EP2607902B1 - Marker für nicht alkoholische Fettlebererkrankung (NAFLD) und nicht alkoholische Steatohepatitis (NASH) sowie Anwendungsverfahren dafür - Google Patents
Marker für nicht alkoholische Fettlebererkrankung (NAFLD) und nicht alkoholische Steatohepatitis (NASH) sowie Anwendungsverfahren dafür Download PDFInfo
- Publication number
- EP2607902B1 EP2607902B1 EP12196378.9A EP12196378A EP2607902B1 EP 2607902 B1 EP2607902 B1 EP 2607902B1 EP 12196378 A EP12196378 A EP 12196378A EP 2607902 B1 EP2607902 B1 EP 2607902B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lipid
- liver
- hete
- nafld
- relative amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims description 237
- 238000000034 method Methods 0.000 title claims description 158
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title description 127
- 150000002632 lipids Chemical class 0.000 claims description 299
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 289
- 239000000194 fatty acid Substances 0.000 claims description 289
- 229930195729 fatty acid Natural products 0.000 claims description 289
- 150000004665 fatty acids Chemical class 0.000 claims description 285
- 239000002207 metabolite Substances 0.000 claims description 196
- 210000004185 liver Anatomy 0.000 claims description 98
- 101100321670 Fagopyrum esculentum FA18 gene Proteins 0.000 claims description 45
- JSFATNQSLKRBCI-VAEKSGALSA-N 15-HETE Natural products CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 claims description 31
- JSFATNQSLKRBCI-UHFFFAOYSA-N 15-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC(O)C=CC=CCC=CCC=CCCCC(O)=O JSFATNQSLKRBCI-UHFFFAOYSA-N 0.000 claims description 28
- 238000012544 monitoring process Methods 0.000 claims description 18
- FFXKPSNQCPNORO-MBYQGORISA-N 19,20-DiHDPA Chemical compound CCC(O)C(O)C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O FFXKPSNQCPNORO-MBYQGORISA-N 0.000 claims description 16
- CQSLTKIXAJTQGA-FLIBITNWSA-N 12,13-DiHOME Chemical compound CCCCCC(O)C(O)C\C=C/CCCCCCCC(O)=O CQSLTKIXAJTQGA-FLIBITNWSA-N 0.000 claims description 13
- 150000000640 6-keto-prostaglandin F1α derivatives Chemical class 0.000 claims description 13
- 238000007681 bariatric surgery Methods 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- IMYZYCNQZDBZBQ-UHFFFAOYSA-N 9,10-epoxyoctadecanoic acid Chemical compound CCCCCCCCC1OC1CCCCCCCC(O)=O IMYZYCNQZDBZBQ-UHFFFAOYSA-N 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- CCPPLLJZDQAOHD-FLIBITNWSA-N vernolic acid Chemical compound CCCCCC1OC1C\C=C/CCCCCCCC(O)=O CCPPLLJZDQAOHD-FLIBITNWSA-N 0.000 claims description 11
- 208000019423 liver disease Diseases 0.000 description 96
- 150000003626 triacylglycerols Chemical class 0.000 description 87
- 210000001124 body fluid Anatomy 0.000 description 72
- 239000010839 body fluid Substances 0.000 description 72
- 210000002381 plasma Anatomy 0.000 description 56
- 231100000240 steatosis hepatitis Toxicity 0.000 description 54
- 101100069385 Toxoplasma gondii GRA6 gene Proteins 0.000 description 50
- 230000007863 steatosis Effects 0.000 description 50
- 150000001840 cholesterol esters Chemical class 0.000 description 44
- 210000002966 serum Anatomy 0.000 description 36
- 206010019708 Hepatic steatosis Diseases 0.000 description 34
- 150000002066 eicosanoids Chemical class 0.000 description 34
- 238000009825 accumulation Methods 0.000 description 29
- 235000021588 free fatty acids Nutrition 0.000 description 27
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 27
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 27
- 230000002440 hepatic effect Effects 0.000 description 26
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 26
- GCZRCCHPLVMMJE-IBGZPJMESA-N 11-HETE Natural products CCCCCC=CC=C[C@H](O)CC=CCC=CCCCC(O)=O GCZRCCHPLVMMJE-IBGZPJMESA-N 0.000 description 23
- 239000000090 biomarker Substances 0.000 description 23
- GCZRCCHPLVMMJE-RLZWZWKOSA-N 11-HETE Chemical compound CCCCC\C=C/C=C/C(O)C\C=C/C\C=C/CCCC(O)=O GCZRCCHPLVMMJE-RLZWZWKOSA-N 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- LOLJEILMPWPILA-AMFHKTBMSA-N 15-oxoprostaglandin F2alpha Chemical compound CCCCCC(=O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O LOLJEILMPWPILA-AMFHKTBMSA-N 0.000 description 21
- 208000004930 Fatty Liver Diseases 0.000 description 20
- 150000003904 phospholipids Chemical class 0.000 description 20
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 19
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 150000008105 phosphatidylcholines Chemical class 0.000 description 18
- PRFXRIUZNKLRHM-HKVRTXJWSA-N prostaglandin B2 Chemical compound CCCCC[C@H](O)\C=C\C1=C(C\C=C/CCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-HKVRTXJWSA-N 0.000 description 18
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 17
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 17
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 17
- DCJBINATHQHPKO-TYAUOURKSA-N (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CC(O)C(O)C\C=C/CCCC(O)=O DCJBINATHQHPKO-TYAUOURKSA-N 0.000 description 16
- NLUNAYAEIJYXRB-HEJOTXCHSA-N 8-HETE Chemical compound CCCCC\C=C/C\C=C/C=C/C(O)C\C=C/CCCC(O)=O NLUNAYAEIJYXRB-HEJOTXCHSA-N 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 15
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 15
- KATOYYZUTNAWSA-DLJQHUEDSA-N 9-hydroxy-5E,7Z,11Z,14Z-eicosatetraenoic acid Chemical compound CCCCC\C=C/C\C=C/CC(O)\C=C/C=C/CCCC(O)=O KATOYYZUTNAWSA-DLJQHUEDSA-N 0.000 description 15
- 102000004895 Lipoproteins Human genes 0.000 description 15
- 108090001030 Lipoproteins Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 229960002986 dinoprostone Drugs 0.000 description 14
- PRFXRIUZNKLRHM-UHFFFAOYSA-N l-prostaglandin B2 Natural products CCCCCC(O)C=CC1=C(CC=CCCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-UHFFFAOYSA-N 0.000 description 14
- LOLJEILMPWPILA-UHFFFAOYSA-N prostaglandin 15-keto-F2alpha Natural products CCCCCC(=O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O LOLJEILMPWPILA-UHFFFAOYSA-N 0.000 description 14
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 14
- MCRJLMXYVFDXLS-QGQBRVLBSA-N 12-HEPE Chemical compound CC\C=C/C\C=C/CC(O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-QGQBRVLBSA-N 0.000 description 13
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- DXOYQVHGIODESM-KROJNAHFSA-N 11,12-EET Chemical compound CCCCC\C=C/CC1OC1C\C=C/C\C=C/CCCC(O)=O DXOYQVHGIODESM-KROJNAHFSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 10
- 229930182558 Sterol Natural products 0.000 description 10
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- -1 cytokeratine Proteins 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 10
- 150000003432 sterols Chemical class 0.000 description 10
- 235000003702 sterols Nutrition 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 9
- 102100031013 Transgelin Human genes 0.000 description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 9
- 238000012353 t test Methods 0.000 description 9
- 239000012491 analyte Substances 0.000 description 8
- 239000003613 bile acid Substances 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001771 impaired effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 8
- 210000004880 lymph fluid Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 7
- BISQPGCQOHLHQK-HDNPQISLSA-N leukotriene B5 Chemical compound CC\C=C/C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O BISQPGCQOHLHQK-HDNPQISLSA-N 0.000 description 7
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 7
- PYSODLWHFWCFLV-VJBFNVCUSA-N leukotriene F4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(O)=O)NC(=O)CC[C@H](N)C(O)=O PYSODLWHFWCFLV-VJBFNVCUSA-N 0.000 description 7
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 7
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 7
- SYAWGTIVOGUZMM-ILYOTBPNSA-N (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid Chemical compound CCCCCC(O)C(O)C\C=C/C\C=C/C\C=C/CCCC(O)=O SYAWGTIVOGUZMM-ILYOTBPNSA-N 0.000 description 6
- PXGPLTODNUVGFL-ZWAKLXPCSA-N 11-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-ZWAKLXPCSA-N 0.000 description 6
- JBSCUHKPLGKXKH-ILYOTBPNSA-N 14,15-EET Chemical compound CCCCCC1OC1C\C=C/C\C=C/C\C=C/CCCC(O)=O JBSCUHKPLGKXKH-ILYOTBPNSA-N 0.000 description 6
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000004077 genetic alteration Effects 0.000 description 6
- 231100000118 genetic alteration Toxicity 0.000 description 6
- 208000016245 inborn errors of metabolism Diseases 0.000 description 6
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- LRPPQRCHCPFBPE-KROJNAHFSA-N (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid Chemical compound CCCCC\C=C/CC(O)C(O)C\C=C/C\C=C/CCCC(O)=O LRPPQRCHCPFBPE-KROJNAHFSA-N 0.000 description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- KJYIVXDPWBUJBQ-UHHGALCXSA-N 11-dehydro-thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O KJYIVXDPWBUJBQ-UHHGALCXSA-N 0.000 description 5
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 description 5
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- 208000015943 Coeliac disease Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010062018 Inborn error of metabolism Diseases 0.000 description 5
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 5
- 208000002720 Malnutrition Diseases 0.000 description 5
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- NPDSHTNEKLQQIJ-UHFFFAOYSA-N dimorphecolic acid Natural products CCCCCC=CC=CC(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 208000006132 lipodystrophy Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012317 liver biopsy Methods 0.000 description 5
- 230000001071 malnutrition Effects 0.000 description 5
- 235000000824 malnutrition Nutrition 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 235000015816 nutrient absorption Nutrition 0.000 description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 4
- GPQVVJQEBXAKBJ-IXEYAUFLSA-N (5e,8e,11e,14e)-16-(3-ethyloxiran-2-yl)hexadeca-5,8,11,14-tetraenoic acid Chemical compound CCC1OC1C\C=C\C\C=C\C\C=C\C\C=C\CCCC(O)=O GPQVVJQEBXAKBJ-IXEYAUFLSA-N 0.000 description 4
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 description 4
- VBQNSZQZRAGRIX-QNEBEIHSSA-N 5,6-EET Chemical compound CCCCC\C=C/C\C=C/C\C=C/CC1OC1CCCC(O)=O VBQNSZQZRAGRIX-QNEBEIHSSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- NPDSHTNEKLQQIJ-ZJHFMPGASA-N alpha-dimorphecolic acid Chemical compound CCCCC\C=C/C=C/C(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-ZJHFMPGASA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 150000001982 diacylglycerols Chemical class 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- GCZRCCHPLVMMJE-JVNZAOJVSA-N (5e,8e,12e,14e)-11-hydroxyicosa-5,8,12,14-tetraenoic acid Chemical compound CCCCC\C=C\C=C\C(O)C\C=C\C\C=C\CCCC(O)=O GCZRCCHPLVMMJE-JVNZAOJVSA-N 0.000 description 3
- FMKLAIBZMCURLI-MELGOLLOSA-N (z)-7-[(5s)-2-oxo-5-(3-oxooctyl)cyclopent-3-en-1-yl]hept-5-enoic acid Chemical compound CCCCCC(=O)CC[C@H]1C=CC(=O)C1C\C=C/CCCC(O)=O FMKLAIBZMCURLI-MELGOLLOSA-N 0.000 description 3
- BBCBJVDLAHSVGC-UHFFFAOYSA-N 12,13-dihydroxyoctadec-2-enoic acid Chemical compound CCCCCC(O)C(O)CCCCCCCCC=CC(O)=O BBCBJVDLAHSVGC-UHFFFAOYSA-N 0.000 description 3
- HNICUWMFWZBIFP-IRQZEAMPSA-N 13(S)-HODE Chemical compound CCCCC[C@H](O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-IRQZEAMPSA-N 0.000 description 3
- HNICUWMFWZBIFP-BSZOFBHHSA-N 13-HODE Chemical compound CCCCCC(O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-BSZOFBHHSA-N 0.000 description 3
- BLWCDFIELVFRJY-QXBXTPPVSA-N 14,15-DiHETE Chemical compound CC\C=C/CC(O)C(O)C\C=C/C\C=C/C\C=C/CCCC(O)=O BLWCDFIELVFRJY-QXBXTPPVSA-N 0.000 description 3
- RGZIXZYRGZWDMI-QXBXTPPVSA-N 14,15-EpETE Chemical compound CC\C=C/CC1OC1C\C=C/C\C=C/C\C=C/CCCC(O)=O RGZIXZYRGZWDMI-QXBXTPPVSA-N 0.000 description 3
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 3
- GFNYAPAJUNPMGH-QNEBEIHSSA-N 5,6-DHET Chemical compound CCCCC\C=C/C\C=C/C\C=C/CC(O)C(O)CCCC(O)=O GFNYAPAJUNPMGH-QNEBEIHSSA-N 0.000 description 3
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 3
- 102000014777 Adipokines Human genes 0.000 description 3
- 108010078606 Adipokines Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 3
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000478 adipokine Substances 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 238000003965 capillary gas chromatography Methods 0.000 description 3
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000007430 reference method Methods 0.000 description 3
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 3
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- DXOYQVHGIODESM-LZXKBWHHSA-N (11S,12R)-EET Chemical compound CCCCC\C=C/C[C@H]1O[C@H]1C\C=C/C\C=C/CCCC(O)=O DXOYQVHGIODESM-LZXKBWHHSA-N 0.000 description 2
- BGNYXRDYZRBOGP-IBGZPJMESA-N (12s)-12-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCC[C@H](O)C=CC=CC=CC=CC=CC(O)=O BGNYXRDYZRBOGP-IBGZPJMESA-N 0.000 description 2
- OWFVSJHRFRIEAK-IBGZPJMESA-N (15S)-15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCC[C@H](O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-IBGZPJMESA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- IZVFFXVYBHFIHY-UHFFFAOYSA-N (3alpha, 5alpha)-Cholest-7-en-3-ol, 9CI Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 IZVFFXVYBHFIHY-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
- DXOYQVHGIODESM-IQCOFVSKSA-N 11,12-epetre Chemical compound CCCCC\C=C\CC1OC1C\C=C/C\C=C\CCCC(O)=O DXOYQVHGIODESM-IQCOFVSKSA-N 0.000 description 2
- NRSPMBWWMXPYGF-UHFFFAOYSA-N 11-(3-pentyloxiran-2-yl)undec-2-enoic acid Chemical compound CCCCCC1OC1CCCCCCCCC=CC(O)=O NRSPMBWWMXPYGF-UHFFFAOYSA-N 0.000 description 2
- MCRJLMXYVFDXLS-UHFFFAOYSA-N 12-(S)-HEPE Natural products CCC=CCC=CCC(O)C=CC=CCC=CCCCC(O)=O MCRJLMXYVFDXLS-UHFFFAOYSA-N 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 description 2
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 description 2
- XYDVGNAQQFWZEF-JPURVOHMSA-N 17,18-DiHETE Chemical compound CCC(O)C(O)C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O XYDVGNAQQFWZEF-JPURVOHMSA-N 0.000 description 2
- SQPXYPGECWUPNI-UHFFFAOYSA-N 17,18-dihydroxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCC(O)C(O)CCCCCCCC=CC=CC=CC=CC(O)=O SQPXYPGECWUPNI-UHFFFAOYSA-N 0.000 description 2
- PIJDPSVRFLPBTJ-UHFFFAOYSA-N 19,20-dihydroxydocosa-2,4,6,8,10-pentaenoic acid Chemical compound CCC(O)C(O)CCCCCCCC=CC=CC=CC=CC=CC(O)=O PIJDPSVRFLPBTJ-UHFFFAOYSA-N 0.000 description 2
- GHCZAUBVMUEKKP-NHIHLBCISA-N 2-[[(4R)-4-[(3R,5S,7S,10S,13R,17R)-3,7-Dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-NHIHLBCISA-N 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- KGIJOOYOSFUGPC-JGKLHWIESA-N 5(S)-HETE Chemical compound CCCCC\C=C/C\C=C/C\C=C/C=C/[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-JGKLHWIESA-N 0.000 description 2
- KDIKFSSEUHHJNR-UHFFFAOYSA-N 5,6-dihydroxyicosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCCC=C(O)C(O)=CC=CC(O)=O KDIKFSSEUHHJNR-UHFFFAOYSA-N 0.000 description 2
- FTAGQROYQYQRHF-FCWZHQICSA-N 5-HEPE Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C=C/C(O)CCCC(O)=O FTAGQROYQYQRHF-FCWZHQICSA-N 0.000 description 2
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- DZUXGQBLFALXCR-BMPPNWMBSA-N 7-[(1R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)\C=C\C1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-BMPPNWMBSA-N 0.000 description 2
- NLUNAYAEIJYXRB-VYOQERLCSA-N 8(S)-HETE Chemical compound CCCCC\C=C/C\C=C/C=C/[C@@H](O)C\C=C/CCCC(O)=O NLUNAYAEIJYXRB-VYOQERLCSA-N 0.000 description 2
- FBUKMFOXMZRGRB-YFHOEESVSA-N 9(10)-EpOME Chemical compound CCCCC\C=C/CC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-YFHOEESVSA-N 0.000 description 2
- ZVJLNRJTGGZUOB-UHFFFAOYSA-N 9-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCC(O)=CC=CC=CC=CC(O)=O ZVJLNRJTGGZUOB-UHFFFAOYSA-N 0.000 description 2
- CUHJQOVOXFVMSQ-UHFFFAOYSA-N 9-hydroxyoctadeca-2,4-dienoic acid Chemical compound CCCCCCCCCC(O)CCCC=CC=CC(O)=O CUHJQOVOXFVMSQ-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 2
- 208000028958 Hyperferritinemia Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 2
- LZOSYCMHQXPBFU-UHFFFAOYSA-N O-decanoylcarnitine Chemical compound CCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C LZOSYCMHQXPBFU-UHFFFAOYSA-N 0.000 description 2
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 description 2
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical compound CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 description 2
- ZGNBLKBZJBJFDG-ZETCQYMHSA-N O-malonyl-D-carnitine Chemical compound C[N+](C)(C)C[C@H](CC(O)=O)OC(=O)CC([O-])=O ZGNBLKBZJBJFDG-ZETCQYMHSA-N 0.000 description 2
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 2
- CXTATJFJDMJMIY-UHFFFAOYSA-N O-octanoylcarnitine Chemical compound CCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C CXTATJFJDMJMIY-UHFFFAOYSA-N 0.000 description 2
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 description 2
- PSHXNVGSVNEJBD-LJQANCHMSA-N O-tetradecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C PSHXNVGSVNEJBD-LJQANCHMSA-N 0.000 description 2
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 2
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 229960001009 acetylcarnitine Drugs 0.000 description 2
- 208000031045 adult-onset type II citrullinemia Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 208000025812 citrin deficiency Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940099347 glycocholic acid Drugs 0.000 description 2
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 2
- XBSQTYHEGZTYJE-OETIFKLTSA-N glycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 XBSQTYHEGZTYJE-OETIFKLTSA-N 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- 239000002035 hexane extract Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- QBYUNVOYXHFVKC-GBURMNQMSA-N taurolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 QBYUNVOYXHFVKC-GBURMNQMSA-N 0.000 description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 2
- 229960001661 ursodiol Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- IOWMKBFJCNLRTC-XWXSNNQWSA-N (24S)-24-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](O)C(C)C)[C@@]1(C)CC2 IOWMKBFJCNLRTC-XWXSNNQWSA-N 0.000 description 1
- FYHRJWMENCALJY-YSQMORBQSA-N (25R)-cholest-5-ene-3beta,26-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC[C@H](CO)C)[C@@]1(C)CC2 FYHRJWMENCALJY-YSQMORBQSA-N 0.000 description 1
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- FBUKMFOXMZRGRB-SQGUUQMOSA-N (9R,10S)-9(10)-EpOME Chemical compound CCCCC\C=C/C[C@@H]1O[C@@H]1CCCCCCCC(O)=O FBUKMFOXMZRGRB-SQGUUQMOSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MCRJLMXYVFDXLS-UOLHMMFFSA-N 12(S)-HEPE Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-UOLHMMFFSA-N 0.000 description 1
- WLKCSMCLEKGITB-DBVSHIMFSA-N 15(S)-HEPE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-DBVSHIMFSA-N 0.000 description 1
- GPQVVJQEBXAKBJ-YQLHGUCYSA-N 17(S),18(R)-EETeTr Chemical compound CC[C@H]1O[C@H]1C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O GPQVVJQEBXAKBJ-YQLHGUCYSA-N 0.000 description 1
- IOWMKBFJCNLRTC-UHFFFAOYSA-N 24S-hydroxycholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(O)C(C)C)C1(C)CC2 IOWMKBFJCNLRTC-UHFFFAOYSA-N 0.000 description 1
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 description 1
- INBGSXNNRGWLJU-UHFFFAOYSA-N 25epsilon-Hydroxycholesterin Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(CCCC(C)(C)O)C)C1(C)CC2 INBGSXNNRGWLJU-UHFFFAOYSA-N 0.000 description 1
- DKISDYAXCJJSLZ-UHFFFAOYSA-N 26-Hydroxy-cholesterin Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(CO)C)C1(C)CC2 DKISDYAXCJJSLZ-UHFFFAOYSA-N 0.000 description 1
- WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 1
- CZDKQKOAHAICSF-JSAMMMMSSA-N 4beta-hydroxycholesterol Chemical compound C1C=C2[C@@H](O)[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 CZDKQKOAHAICSF-JSAMMMMSSA-N 0.000 description 1
- FTAGQROYQYQRHF-OTZRFASISA-N 5-HEPE Natural products CCC=C/CC=C/CC=C/CC=C/C=C/C(O)CCCC(=O)O FTAGQROYQYQRHF-OTZRFASISA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-AWBHSAGMSA-N 7a-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2C1[C@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-AWBHSAGMSA-N 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- HVYWMOMLDIMFJA-IFAPJKRJSA-N Cholesterol_d7 Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])[C@@]1(C)CC2 HVYWMOMLDIMFJA-IFAPJKRJSA-N 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 1
- 101100223822 Dictyostelium discoideum zfaA gene Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 101710199726 Glycerol-3-phosphate acyltransferase 1 Proteins 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000999373 Homo sapiens Interferon-related developmental regulator 2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 description 1
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100036480 Interferon-related developmental regulator 2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
- SVJLJQBGUITFLI-UHFFFAOYSA-N O-icosanoylcarnitine Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C SVJLJQBGUITFLI-UHFFFAOYSA-N 0.000 description 1
- MJLXQSQYKZWZCB-DQFWFXSYSA-N O-linoleyl-L-carnitine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C MJLXQSQYKZWZCB-DQFWFXSYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 101150032799 PE15 gene Proteins 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 108010030678 Phosphatidylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 102000005920 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010045254 Type II hyperlipidaemia Diseases 0.000 description 1
- 208000032001 Tyrosinemia type 1 Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- YEYCQJVCAMFWCO-PXBBAZSNSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] formate Chemical compound C1C=C2C[C@@H](OC=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YEYCQJVCAMFWCO-PXBBAZSNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000012152 algorithmic method Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- DKPMWHFRUGMUKF-CRKPLTDNSA-N beta-muricholic acid Chemical compound C([C@H]1[C@H](O)[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DKPMWHFRUGMUKF-CRKPLTDNSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- NYOXRYYXRWJDKP-GYKMGIIDSA-N cholest-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 NYOXRYYXRWJDKP-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- BHTRKEVKTKCXOH-BJLOMENOSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-BJLOMENOSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 201000007972 tyrosinemia type I Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/02—Triacylglycerols
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Definitions
- Non-alcoholic steatohepatitis is the most common chronic liver disease in the United States.
- NASH is a fatty inflammation of the liver and a major cause of cirrhosis, fibrosis and liver failure.
- the disease is progressive, starting as steatosis or nonalcoholic fatty liver disease (NAFLD), progressing to an inflamed fatty liver (NASH), and eventually leading to cirrhosis and fibrosis.
- NAFLD or NASH requires liver biopsy as there are no laboratory tests for either of these diseases.
- the diagnosis of NASH requires the presence of fat, inflammation, and centrolobular (zone 3) ballooning degeneration with either pericellular fibrosis or Mallory bodies. This distinction is important because NASH is believed to be a progressive liver disease which can lead to cirrhosis and even hepatocellular carcinoma.
- NAFLD Newcastle disease virus
- U.S. population The prevalence of NAFLD in the U.S. population is -20-23%, and may be as high as 33%, and the prevalence of NASH in the U.S. population is 2-3%.
- Some NASH patients will progress to late stage disease: approximately 15-50% of NASH patients progress to severe fibrosis, and approximately 7-16% progress to cirrhosis.
- the rate of liver-specific mortality in NASH cirrhotics is approximately 10% per decade.
- Serum aminotransferase elevations and hepatic imaging studies showing changes suggestive of fatty liver are not adequate alone or in combination to distinguish NAFLD from NASH. It is difficult to evaluate the natural history and course of NAFLD or better define its need for therapy or intervention.
- the causes of NAFLD and NASH are not well defined, but they typically occur in association with obesity, insulin resistance or type II diabetes, and hyperlipidemia, suggesting that fatty liver and NASH are hepatic manifestations of the dysmetabolic syndrome, and might better be referred to as metabolic steatohepatitis (MESH).
- MASH metabolic steatohepatitis
- the liver is the principal metabolic organ for all lipid metabolic pathways. Under normal conditions, the liver regulates blood lipid levels and manages complex lipid biosynthesis and transport consistent with the energy balance in the body. Thus, liver damage and dysfunction can lead to severe consequences at the organism level.
- NAFLD has been traditionally viewed to be a benign disease, but a subset of patients will progress to NASH and end-stage liver disease requiring a liver transplant. Because NAFLD is a silent disease, diagnosis at present can be made only through needle biopsy. If recognized, treatment methods for NAFLD and NASH can slow or reverse the disease in some individuals, particularly in early stage disease.
- Pawlosky et al. reports on the measurement of the concentration of several polyunsaturated fatty acids in total lipid extracts from the livers of subjects diagnosed with alcoholic liver disease.
- Araya et al. provides an assessment of the levels of PUFA (polyunsaturated fatty acids) in liver total lipids, triacylglycerols (triglycerides) and phospholipids of NAFLD patients in relation to those in adipose tissue and hepatic indexes related to oxidative stress as factors contributing to hepatic steatosis.
- PUFA polyunsaturated fatty acids
- triacylglycerols triglycerides
- phospholipids of NAFLD patients in relation to those in adipose tissue and hepatic indexes related to oxidative stress as factors contributing to hepatic steatosis.
- WO 2006/031963 provides methods of using certain metabolite markers for predicting weight development or its related conditions of a subject.
- the invention provides a method of diagnosing or monitoring non-alcoholic fatty liver disease (NAFLD) in a subject, comprising:
- a subject e.g., a human
- monitoring diagnosing, classifying, assessing the severity, and/or assessing the progression or regression of a liver disorder in the subject.
- the liver disorder is hepatic impairment, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, or non-alcoholic steatohepatitis (NASH).
- the methods comprise determining the amount of one or more lipid metabolites (e.g., fatty acids and/or eicosanoids) in a body fluid from the subject.
- a method of diagnosing or monitoring a liver disorder in a subject comprising determining an amount of one or more lipid metabolites in one or more samples from a body fluid of the subject, and correlating the amount(s) of the one or more lipid metabolites with the presence of the liver disorder.
- the lipid metabolites comprise fatty acids and/or eicosanoids.
- the liver disorder is hepatic impairment, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, or non-alcoholic steatohepatitis (NASH).
- the one or more lipid metabolites are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm 18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:1n7; TGMUFA; TGn7; TGS
- the amount(s) of the one or more fatty acids are the relative amount(s) of the one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in one or more samples.
- the methods can, in some embodiments, further comprise comparing the amount(s) of the one or more lipid metabolites to one or more references (e.g., a normal control).
- the amounts of two or more, three or more, four or more, five or more, or six or more lipid metabolites are determined.
- the sample(s) are selected from the group consisting of blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid.
- Also disclosed herein is a method of diagnosing or monitoring a liver disorder in a subject, which comprises determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject, and correlating the relative amount(s) with the presence of the liver disorder; wherein the liver disorder is hepatic impairment, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, or non-alcoholic steatohepatitis (NASH).
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- the one or more fatty acids are selected from the group consisting of: PC 18:3n6; PC20:3n6; CEI 4:0; CE 16: 1 n7; CE 18: 1 n9; CEMUFA; CEn7; CE 18: 1 n7; CE 18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC 14:0; PC 16: 1 n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:1n7; TGMUFA; TGn7
- the method comprises the step of comparing the relative amount of one or more fatty acids to a reference.
- the liver disorder is NASH, and the method further comprises the step of determining the level of an eicosanoid in a body fluid.
- the relative amounts of two or more, three or more, four or more, five or more, or six or more fatty acids are determined.
- the sample is selected from the group consisting of blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid.
- Also disclosed herein is a method of assessing the level of triglycerides in the liver of a subject, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject, wherein the lipid metabolite is a fatty acid present in a lipid class, and wherein the lipid class is selected from the group consisting of free fatty acids, total fatty acids, triglycerides, cholesterol esters, phosphatidylcholines, and phosphatidylethanolamines.
- the amount of the metabolite is the relative amount of the fatty acid to total fatty acid content in the lipids of one or more lipid classes in the sample.
- the fatty acid is selected from the group consisting of: PC18:3n6; PC20:3n6; CE 14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC 18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:1n7; TGMUFA; TGn7; TGSFA; TL14
- the method further comprises the step of comparing the relative amount of one or more fatty acid to a reference.
- the sample is selected from the group consisting of blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid.
- the method comprises determining the amount of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, or at least 20 lipid metabolites.
- the lipid metabolite is a fatty acid present in a lipid class.
- the lipid class is selected from the group consisting of: free fatty acids, total fatty acids, triglycerides, cholesterol esters, phosphatidylcholines, and phosphatidylethanolamines.
- the lipid class is selected from the group consisting of: neutral lipids, free fatty acids, total fatty acids, triglycerides, cholesterol esters, phospholipids, phosphatidylcholines, and phosphatidylethanolamines. In some embodiments, the lipid class is selected from the group consisting of: neutral lipids, total fatty acids, cholesterol esters, and phospholipids. In some embodiments, the amount of the metabolite is the relative amount of a fatty acid to total fatty acid content in the lipids of one or more lipid classes in the sample.
- the relative amount is selected from the group consisting of: (a) the relative amount of a fatty acid to total fatty acid content in triglycerides in the sample; (b) the relative amount of a fatty acid to total fatty acid content in free fatty acids in the sample; (c) the relative amount of a fatty acid to total fatty acid content in phosphatidylcholines in the sample; (d) the relative amount of a fatty acid to total fatty acid content in phosphatidylethanolamines in the sample; (e) the relative amount of a fatty acid to total fatty acid content in cholesterol esters in the sample; and (f) the relative amount of a fatty acid to total fatty acid content in all lipids in the sample.
- the fatty acid is selected from the group consisting of: TG14:0, TG14:1n5, TG16:0, TG18:1n7, TGMUFA, TGn7, TGSFA, TG16:1n7, PC14:0, PC16:1n7, PC18:1n7, PC18:1n9, PC18:3n3, PC18:3n6, PC18:4n3, PC20:0, PC20:1n9, PC20:2n6, PC20:3n6, PC20:4n3, PC20:5n3, PC22:0, PC22:1n9, PC24:0, PC24:1n9, PCdm, PCdm18:0, PCdm18:1n7, PCSFA, CE16:1n7, CE18:1n7, CE18:1n9, CE18:2n6, CE18:3n6, CE22:5n3, CE22:6n3, CEMUFA, CEn6, CEn7, CEPUFA,
- the fatty acid is TG20:4n6.
- the sample is selected from the group consisting of blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid.
- the sample is selected from the group consisting of blood, plasma, serum, or isolated lipoprotein fraction.
- the sample is lymph or cerebrospinal fluid.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of one or more fatty acids to total fatty acid content in triglycerides in a sample from a body fluid of the subject.
- the one or more fatty acids are selected from the group consisting of TG14:0, TG14:1n5, TG16:0, TG18:1n7, TGMUFA, TGn7, TGSFA, and TG16:1n7.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, accumulation of triglycerides in the liver is indicated.
- the one or more fatty acids are selected from the group consisting of TG15:0, TG18:2n6, TG18:3n3, TG20:0, TG20:2n6, TG20:3n6, TG20:3n9, TG20:4n6, TG20:5n3, TG22:0, TG22:1n9, TG22:2n6, TG22:4n6, TG22:5n3, TG22:5n6, TG22:6n3, TG24:0, TG24:1n9, TGn3, TGn6, and TGPUFA.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the triglycerides in a sample from a body fluid previously obtained from the subject.
- the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the triglycerides found in one or more samples from a body fluid of one or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of a fatty acid to total fatty acid content in free fatty acids in a sample from a body fluid of the subject.
- the fatty acid is FA 16:1n7.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the free fatty acids in a sample from a body fluid previously obtained from the subject.
- the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the free fatty acids found in one or more samples from a body fluid of one or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of one or more fatty acids to total fatty acid content in phosphatidylcholines in a sample from a body fluid of the subject.
- the one or more fatty acids are selected from the group consisting of PC14:0, PC16:1n7, PC18:1n7, PC18:1n9, PC18:3n3, PC18:3n6, PC18:4n3, PC20:0, PC20:1n9, PC20:2n6, PC20:3n6, PC20:4n3, PC20:5n3, PC22:0, PC22:1n9, PC24:0, PC24:1 n9, PCdm, PCdm18:0, PCdm18:1n7, and PCSFA.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, accumulation of triglycerides in the liver is indicated.
- the one or more fatty acids are selected from the group consisting of PC18:1n7, PC20:4n6, PC22:5n6, PCn6, PCPUFA, and PC22:5n3.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the phosphatidylcholines in a sample from a body fluid previously obtained from the subject. In some embodiments, the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the phosphatidylcholines found in one or more samples from a body fluid of one or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of a fatty acid to total fatty acid content in phosphatidylethanolamines in a sample from a body fluid of the subject.
- the fatty acid is PE20:4n6.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the phosphatidylethanolamines in a sample from a body fluid previously obtained from the subject.
- the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the phosphatidylethanolamines found in one or more samples from a body fluid of one or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of one or more fatty acids to total fatty acid content in a sample from a body fluid of the subject.
- the one or more fatty acids are selected from the group consisting of 14:0, 16:0, 18:0, 16:1n7, 18:1n7, 18:1n9, 18:3n6, and 18:4n3.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, accumulation of triglycerides in the liver is indicated.
- the one or more fatty acids are selected from the group consisting of 15:0, 20:0, 22:0, 18:2n6, 20:2n6, 20:3n9, 20:4n3, 20:4n6, 22:4n6, and 22:5n6.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in a sample from a body fluid previously obtained from the subject.
- the reference represents the relative amount of the one or more fatty acids to total fatty acid content found in one or more samples from a body fluid of one or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of one or more fatty acids to total fatty acid content in cholesterol esters in a sample from a body fluid of the subject.
- the one or more fatty acids are selected from the group consisting of CE16:1n7, CE18:1n7, CE18:1n9, CE18:2n6, CE18:3n6, CE22:5n3, CE22:6n3, CEMUFA, CEn6, CEn7, CEPUFA, CE14:0.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, accumulation of triglycerides in the liver is indicated.
- the one or more fatty acids are selected from the group consisting of CE14:1n5, CE18:0, CE20:0, CE20:1n9, CE20:2n6, CE20:3n9, CE20:4n3, CE20:4n6, CE22:0, CE22:2n6, CE24:0, and CESFA.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the cholesterol esters in a sample from a body fluid previously obtained from the subject. In some embodiments, the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the cholesterol esters found in one or more samples from a body fluid of one-or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of one or more fatty acids to total fatty acid content in neutral lipids in a sample from a body fluid of the subject.
- the one or more fatty acids are selected from the group consisting of TG14:0, TG14:1n5, TG16:0, TG18:1n7, TGMUFA, TGn7, TGSFA, and TG16:1n7.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, accumulation of triglycerides in the liver is indicated.
- the one or more fatty acids are selected from the group consisting of TG15:0, TG18:2n6, TG18:3n3, TG20:0, TG20:2n6, TG20:3n6, TG20:3n9, TG20:4n6, TG20:5n3, TG22:0, TG22:1n9, TG22:2n6, TG22:4n6, TG22:5n3, TG22:5n6, TG22:6n3, TG24:0, TG24:1n9, TGn3, TGn6, TGPUFA, and FA16:1n7.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the neutral lipids in a sample from a body fluid previously obtained from the subject.
- the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the neutral lipids found in one or more samples from a body fluid of one or more subjects having normal livers.
- the level of accumulation of triglycerides in the liver of a subject is assessed, comprising determining a relative amount of one or more fatty acids to total fatty acid content in phospholipids in a sample from a body fluid of the subject.
- the one or more fatty acids are selected from the group consisting of PC14:0, PC16:1n7, PC18:1n7, PC18:1n9, PC18:3n3, PC18:3n6, PC18:4n3, PC20:0, PC20:1n9, PC20:2n6, PC20:3n6, PC20:4n3, PC20:5n3, PC22:0, PC22:1n9, PC24:0, PC24:1n9, PCdm, PCdm18:0, PCdm18:1n7, and PCSFA.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, accumulation of triglycerides in the liver is indicated.
- the one or more fatty acids are selected from the group consisting of PC 18:1n7, PC20:4n6, PC22:5n6, PCn6, PCPUFA, PC22:5n3, and PE20:4n6.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, accumulation of triglycerides in the liver is indicated.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the phospholipids in a sample from a body fluid previously obtained from the subject. In some embodiments, the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the phospholipids found in one or more samples from a body fluid of one or more subjects having normal livers.
- the method further comprises determining at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 additional relative amounts, wherein the relative amount(s) is the relative amount of a fatty acid to total fatty acid content in the lipids of one or more lipid classes in the sample.
- the method further comprises determining an additional relative amount, wherein the additional relative amount is selected from the group consisting of: (a) the relative amount of a fatty acid to total fatty acid content in triglycerides in the sample; (b) the relative amount of a fatty acid to total fatty acid content in free fatty acids in the sample; (c) the relative amount of a fatty acid to total fatty acid content in phosphatidylcholines in the sample; (d) the relative amount of a fatty acid to total fatty acid content in phosphatidylethanolamines in the sample; (e) the relative amount of a fatty acid to total fatty acid content in cholesterol esters in the sample; and (f) the relative amount of a fatty acid to total fatty acid content in all lipids in the sample.
- the additional relative amount is selected from the group consisting of: (a) the relative amount of a fatty acid to total fatty acid content in triglycerides in the sample; (b) the relative amount of a fatty
- the additional relative amount is selected from the group consisting of: (a) a relative amount of one or more fatty acids to total fatty acid content in triglycerides in a sample from a body fluid of the subject, wherein the one or more fatty acids are selected from the group consisting of TG14:0, TG14:1n5, TG16:0, TG18:1n7, TGMUFA, TGn7, TGSFA, and TG16:1n7; (b) a relative amount of one or more fatty acids to total fatty acid content in phosphatidylcholines in a sample from a body fluid of the subject, wherein the one or more fatty acids are selected from the group consisting of PC14:0, PC16:1n7, PC18:1n7, PC18:1n9, PC18:3n3, PC18:3n6, PC18:4n3, PC20:0, PC20:1n9, PC20:2n6, PC20:3n6, PC20:
- the method may further comprise the step of comparing the additional relative amount to an additional reference, wherein if the additional relative amount is greater than the additional reference, accumulation of triglycerides in the liver is indicated.
- the additional relative amount is selected from the group consisting of: (a) a relative amount of one or more fatty acids to total fatty acid content in triglycerides in a sample from a body fluid of the subject, wherein the one or more fatty acids are selected from the group consisting of TG15:0, TG18:2n6, TG18:3n3, TG20:0, TG20:2n6, TG20:3n6, TG20:3n9, TG20:4n6, TG20:5n3, TG22:0, TG22:1n9, TG22:2n6, TG22:4n6, TG22:5n3, TG22:5n6, TG22:6n3, TG24:0, TG24:1n9, TGn3, TGn3,
- Methods of assessing the level of triglycerides in the liver of a subject may be used in diagnosing, monitoring, assessing the severity, and/or assessing the progression or regression of a liver disorder, wherein the liver disorder is selected from the group consisting of: hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, and NASH.
- the method of diagnosing a liver disorder in a subject comprises (a) determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject; (b) correlating the relative amount with the presence of the liver disorder; and wherein the liver disorder is hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH.
- the method of assessing the severity of a liver disorder in a subject comprises (a) determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject; (b) correlating the relative amount with severity of the liver disorder; and wherein the liver disorder is hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH.
- the method of monitoring a liver disorder in a subject comprises (a) determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject; (b) correlating the relative amount with the state of the liver disorder; and wherein the liver disorder is hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH.
- the method of assessing the progression or regression of a liver disorder in a subject comprises (a) determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject; (b) correlating the relative amount with the state of the liver disorder; and wherein the liver disorder is hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH.
- the relative amount is measured at two or more time points.
- the method of monitoring, assessing the severity, or assessing the progression or regression of the liver disorder is used to determine the subject's response to treatment.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH is indicated. In some embodiments, the method may comprise the step of comparing the relative amount to a reference, wherein if the relative amount is lower than the reference, hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH is indicated.
- the method may further comprise the step of determining an additional relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject.
- the liver disorder is associated with one or more conditions selected from the group consisting of: hepatitis, HIV infection, HBV infection, HCV infection, viral-induced steatosis, and steatosis induced by a non-viral infectious agent.
- the liver disorder is associated with drug-induced steatosis.
- the drug-induced steatosis is induced by tamoxifen, an uncoupling protein inhibitor, Isoniazid, Rifampicin, a fibrate, or a peroxisome proliferator-activated receptor (PPAR) agonist.
- the liver disorder is associated with one or more conditions selected from the group consisting of: obesity, polycystic ovary syndrome (PCOS), diabetes, insulin resistance, and metabolic disorder.
- the liver disorder associated with one or more conditions selected from the group consisting of: alcoholic fatty liver disease and alcoholic steatohepatitis.
- the liver disorder is associated with an inborn error of metabolism or a genetic alteration.
- the inborn error of metabolism or genetic alteration is selected from the group consisting of citrin deficiency, hemochromatosis, and hyperferritinemia.
- the liver disorder is associated with toxin-induced steatosis or toxin-induced steatohepatitis.
- the toxin-induced steatosis or toxin-induced steatohepatitis is induced by carbon tetrachloride.
- the liver disorder is associated with one or more conditions selected from the group consisting of: malnutrition, impaired nutrient absorption, celiac disease, and lipodystrophy.
- the liver disorder is associated with bariatric surgery or a liver transplant.
- the method further comprises: (c) determining the level of malonyl-CoA or malonyl carnitine in a body fluid or cellular sample from the subject, wherein a higher than normal level is indicative of steatosis, NAFLD, or NASH; (d) determining the level of an acylcarnitine, free carnitine, or butyrobetaine in a body fluid or cellular sample from the subject, wherein a lower than normal level is indicative of hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or "NASH; and/or (e) determining the level of a sterol or bile acid in a body fluid or cellular sample from the subject, wherein a higher than normal level is indicative of hepatic impairment, hepatic steatosis
- the acylcarnitine is an acylcamitine in Table 3.
- the sterol or bile acid is a sterol or bile acid in Table 4.
- the method further comprises the step of determining the level of an eicosanoid in a body fluid or cellular sample from the subject, wherein a higher than normal level is indicative of NASH.
- the eicosanoid is an eicosanoid in Table 2.
- the method further comprises the step of determining the level of a cytokine, cytokeratine, chemokine, adipokine, or leptin in a body fluid or cellular sample from the subject.
- the cytokine, cytokeratine, chemokine, adipokine, or leptin is TNF, IL-6, CCL2/MCP-1 or CCL19, and a higher than normal level is indicative of NASH.
- the cytokine or cytokeratine is IL-8, IL- 18, cytokeratine 8 or cytokeratine 18, and a lower than normal level is indicative of NASH.
- the method further comprises the step of (a) performing a physical examination of the subject; (b) measuring the level of an aminotransferase in the blood of the subject; or (c) obtaining an image of the liver of the subject.
- the subject is a mammal, such as a human.
- the mammal is a primate.
- the subject is a liver graft donor candidate, is being evaluated for bariatric surgery, has had bariatric surgery, or is being monitored for weight loss.
- kits for use in the methods of the invention comprises (a) an antibody to the marker (e.g., fatty acid or eicosanoid); and (b) instructions for use.
- the kit further comprises: (c) a second antibody to a second marker (e.g., fatty acid or eicosanoid).
- the kit further comprises: (d) a third antibody to a third marker (e.g., fatty acid or eicosanoid).
- the present disclosure encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, but also the main group absent one or more of the group members.
- the present disclosure also envisages the explicit exclusion of one or more of any of the group members in the claimed disclosure.
- the invention provides testing methods that can be used to diagnose, classify, and/or monitor patients with NAFLD associated with increased liver triglyceride levels, , and to identify patients at risk of transitioning from NAFLD to steatohepatitis or NASH.
- Hepatic triglycerides levels determine the severity of steatosis. Because the accumulation of triglyceride within liver (steatosis) is the result of inadequate export of triglyceride out of liver via very low density lipoprotein (VLDL) secretion, the absolute amount of triglyceride in plasma is not a consistent measure of the magnitude of steatosis.
- VLDL very low density lipoprotein
- fatty acids labeled with a prefix “CE”, “DG”, “FA”, “LY”, “PC”, “PE”, “SM”,”TG,” or “TL” refer to the indicated fatty acids present within cholesterol esters, diglycerides, free fatty acids, lysophosphatidylcholines, phosphatidylchol ines, phosphatidylethanolamines, sphingomyelins, triglycerides, and total lipids, respectively, in a sample.
- the indicated fatty acid components are quantified as a proportion of total fatty acids within the lipid class indicated by the prefix.
- LC LC following a prefix “CE”, “DG”, “FA”, “LY”, “PC”, “PE”, “SM”, “TG,” or “TL” refers to the amount of the total lipid class indicated by the prefix in the sample (e.g., the concentration of lipids of that class expressed as nMoles per gram of serum or plasma).
- PC18:2n6 indicates the percentage of plasma or serum phosphatidylcholine comprised of linoleic acid (18:2n6)
- TGLC indicates the absolute amount (e.g., in nMoles per gram) of triglyceride present in plasma or serum.
- the liver disorder is steatosis and/or NAFLD and the one or more lipid metabolites are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20: I n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG 14:0; TG14:1n5; TG16:0; TG16:1n7; TG
- the lipid metabolites that are measured comprise one or more fatty acid and the amount of each of the fatty acids is the relative amount of the fatty acid to total fatty acid content in the lipids of the lipid class (as indicated by the prefix preceding the fatty acid).
- metabolites that are "positively associated” or “positively correlated” with a disorder include those metabolites whose concentrations generally increase with the disorder relative to normal control subjects or a normal control reference.
- Metabolites that are "negatively associated” or “negatively correlated” with a disorder generally include those metabolites whose concentrations decrease with the disorder relative to normal control subjects or a normal control reference.
- the liver disorder is NASH and the one or more lipid metabolites are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:1n7; TGMUFA; TG14:
- the lipid metabolites that are measured comprise one or more fatty acid and the amount of each of the fatty acids is the relative amount of the fatty acid to total fatty acid content in the lipids of the lipid class (as indicated by the prefix preceding the fatty acid).
- a lipid metabolite that is a relative proportion (shown in darker grey) of a triglyceride (or any other lipid class) can be measured in a body fluid, such as serum or plasma, as a quantitative measure of the relative proportion of that lipid metabolite in hepatic triglycerides (or other lipid class). If this relative proportion of lipid metabolite (or a collection of lipid metabolites) correlates with the hepatic triglyceride concentration, it serves as a quantitative surrogate of hepatic steatosis, independent of the flux of triglycerides from liver in VLDL. Thus, the mole percentage or other relative amount of a particular fatty acid within a particular lipid class may be used as a quantitative surrogate for steatosis.
- the relative amount (e.g., mole percentage or weight percent) of a single lipid metabolite may be used in the methods of the invention.
- the relative amounts (e.g., mole percentages or weight percentages) of two or more lipid metabolites may be used in the methods of the invention, for example, 2, 3, 4, 5, 10, 15, 20, or more lipid metabolites.
- the relative amount is the mole percentage.
- the relative amount is the weight percentage.
- the amounts of one or more biomarkers, as defined below, in a sample from the subject may be used in the methods of the invention, in addition to the amount of one or more lipid metabolites.
- the amount of the biomarker is the absolute amount of the biomarker in the sample.
- the amount of the biomarker is the concentration of the biomarker in the sample.
- a formula containing the levels of one or more lipid metabolites as variables includes any mathematical formula, model, equation, or expression established based on mathematic or statistical principles or methods using the values of one or more lipid metabolites as variables.
- any suitable mathematic analyses can be used to analyze the net effect of two or more lipid metabolites with respect to projecting the condition of the liver of a subject.
- methods such as multivariate analysis of variance, multivariate regression, multiple regression can be used to determine relationships between dependent variables, and independent variables.
- Clustering including both hierarchical and nonhierarchical methods, as well as nonmetric Dimensional Scaling can be used to determine associations among variables and among changes in those variables.
- principle component analysis is a common way of reducing the dimension of studies, and can be used to interpret the variance-covariance structure of a data set.
- Principle components may be used in such applications as multiple regression and cluster analysis.
- Factor analysis is used to describe the covariance by constructing "hidden" variables from the observed variables.
- Factor analysis may be considered an extension of principle component analysis, where principle component analysis is used as parameter estimation along with the maximum likelihood method.
- simple hypothesis such as equality of two vectors of means can be tested using Hotelling's T squared statistic.
- a formula containing one or more lipid metabolites as variables is established by using regression analyses, e.g., multiple linear regressions.
- Examples of formulas developed include, without any limitation, the following: k + k 1 FA 1 + k 2 FA 2 + k 3 FA 3 k ⁇ k 1 FA 1 + k 2 FA 2 + k 3 FA 3 k + k 1 FA 1 ⁇ k 2 FA 2 + k 3 FA 3 k + k 1 FA 1 + k 2 FA 2 ⁇ k 3 FA 3 k ⁇ k 1 FA 1 ⁇ k 2 FA 2 + k 3 FA 3 k + k 1 FA 1 ⁇ k 2 FA 2 ⁇ k 3 FA 3 k ⁇ k 1 FA 1 + k 2 FA 2 ⁇ k FA 3 k ⁇ k 1 FA 1 + k 2 FA 2 ⁇ k FA 3 k ⁇ k 1 FA 1 + k 2 FA 2 ⁇ k FA 3 k ⁇ k 1 FA 1 + k 2 FA 2
- the formulas may use one or more lipid metabolites as variables, such as 1, 2, 3, 4, 5, 10, 15, 20, or more lipid metabolites.
- the constants of these formulas can be established by using a set of data obtained from known liver conditions.
- the levels of lipid metabolites used in these formulas can be either the levels at a time point or changes of levels over a period of time.
- mathematic formulas established using lipid metabolites can be used to either qualitatively or quantitatively assess the liver condition of a subject over a period of time.
- a formula having one or more lipid metabolites as variables can be used to directly calculate the liver condition of a subject.
- the net value of a formula containing one or more lipid metabolites can be compared to the standard value of such formula corresponding to a liver condition pattern, e.g. progression or regression of fatty liver disease, and the results of such comparison can be used to project liver condition development.
- a subject having a net value of a formula similar to or within the range of the standard value of such formula that is assigned to or associated with a progression of a liver condition is likely to experience a progression over a period of time.
- a subject having a net value of a formula similar to or within the range of the standard values of such formula that is assigned to or associated with a regression is likely to experience a regression of their liver condition over a period of time.
- these mathematical modeling methods and formulas may also be used when analyzing the net effects rendered by one or more lipid metabolites and one or more biomarkers.
- Lipid metabolites may be measured in a body fluid.
- body fluids include, for example, fluids such as blood, plasma, serum, isolated lipoprotein fractions, saliva, urine, lymph, cerebrospinal fluid, and bile.
- the lipid metabolite is measured in a blood-based body fluid, such as blood, plasma, serum, or lipoprotein fractions.
- the lipid metabolite is measured in plasma.
- the lipid metabolite is measured in serum.
- the invention provides methods in which the amounts of one or more, two or more, three or more, four or more, five or more, or six or more lipid metabolites are determined.
- the lipid metabolites which are measured comprise a pair of lipid metabolites selected from the group consisting of the one or more lipid metabolites comprise a pair of lipid metabolites selected from the group consisting of (a) 15-HETE and 15-keto-PGF2 ⁇ ; (b) TG18:1n7 and PC20:3n6; (c) 11-HETE and CE22.6n3; (d) 11-HETE and PCTL; and (e) PC22:6n3 and PC18:3n3.
- the method is a method of classifying a liver disorder as NASH versus NAFLD.
- the lipid metabolite is a fatty acid present within a particular lipid class.
- Lipid metabolites encompass, without limitation, each of the metabolites listed in Table 1 below, as well as each of the metabolites listed in Tables 7 and 8 of Example 4, below.
- the lipid metabolite is TG20:4n6.
- the method may involve measuring the amount of more than one lipid metabolite, such as 2, 3, 4, 5, 10, 15, 20, or more lipid metabolites.
- two or more lipid metabolites in Table 1 are measured.
- three or more lipid metabolites in Table 1 are measured.
- five or more lipid metabolites in Table 1 are measured.
- two or more lipid metabolites in Tables 7 and/or 8 are measured. In some embodiments, three or more lipid metabolites in Tables 7 and/or 8 are measured. In some embodiments, five or more lipid metabolites in Tables 7 and/or 8 are measured. In some embodiments, the lipid metabolite is positively correlated with liver triglyceride levels. In some embodiments, the lipid metabolite is negatively correlated with liver triglyceride levels. In some embodiments, the lipid metabolite is measured as a relative amount within that particular lipid class. In some embodiments, the lipid metabolite is measured as a mole percentage within that particular lipid class.
- the lipid metabolite is measured as a weight percentage within that particular lipid class.
- Table 1 Blood-based Lipid Metabolite Markers of Hepatic Steatosis (Based on Mole Percentage) Lipid Class Positive Correlates Negative Correlates Triglycerides TG14:0 TG15:0 TG14:1n5 TG18:2n6 TG16:0 TG18:3n3 TG18:1n7 TG20:0 TGMUFA TG20:2n6 TGn7 TG20:3n6 TGSFA TG20:3n9 TG16:1n7 TG20:4n6 TG20:5n3 TG22:0 TG22:1n9 TG22:2n6 TG22:4n6 TG22:5n3 TG22:5n6 TG22:6n3 TG24:0 TG24:1n9 TGn3 TGn6 TGPUFA Free Fatty Acids FA16:1n7 P
- TG fatty acids present within triglycerides, free fatty acids, phosphatidylcholines, phosphatidylethanolamines, and cholesterol esters, respectively.
- TG14:0 indicates the fatty acid 14:0 present within triglycerides.
- 14:0 indicates the fatty acid 14:0 present within total fatty acids.
- the lipid class may be, for example, neutral lipids, phospholipids, free fatty acids, total fatty acids, triglycerides, cholesterol esters, phosphatidylcholines, phosphatidylethanolamines, diglycerides, or lysophosphatidylcholines.
- the lipid class is selected from the group consisting of neutral lipids, phospholipids, free fatty acids, total fatty acids, triglycerides, cholesterol esters, phosphatidylcholines, and phosphatidylethanolamines.
- the lipid class is selected from the group consisting of neutral lipids, phospholipids, total fatty acids, and cholesterol esters.
- the lipid class is selected from the group consisting of free fatty acids, total fatty acids, triglycerides, cholesterol esters, phosphatidylcholines, and phosphatidylethanolamines. In some embodiments, the lipid class is free fatty acids. In some embodiments, the lipid class is total fatty acids. In some embodiments, the lipid class is triglycerides. In some embodiments, the lipid class is cholesterol esters. In some embodiments, the lipid class is phosphatidylcholines. In some embodiments, the lipid class is phosphatidylethanolamines. In some embodiments, the lipid class is phospholipids. In some embodiments, the lipid class is neutral lipids. In some embodiments, the lipid class is diglycerides. In some embodiments, the lipid class is sphingomyelins.
- one or more lipid metabolites are measured that comprise one or more fatty acids.
- one or more lipid metabolites are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5
- one or more fatty acids are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:In7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:1n7; TGMUFA; TGn7; TGSFA; TG14:0;
- the liver disorder is steatosis and/or NAFLD and one or more lipid metabolites are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:
- the liver disorder is NASH and one or more lipid metabolites are selected from the group consisting of: PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; CEn6; CEPUFA; PC14:0; PC16:1n7; PC18:1n9; PC18:3n3; PC18:4n3; PC20:0; PC20:1n9; PC20:4n3; PC20:5n3; PC22:0; PC22:1n9; PC24:0; PC24:1n9; PCdm; PCdm18:0; PCdm18:1n7; PCSFA; TG 14:0; TG14:1n5; TG16:0; TG16:1n7; TG18:1n7; TGMUFA;
- the amounts of the fatty acids are determined from a blood, serum, plasma, or isolated lipoprotein fraction sample.
- the present invention provides methods in which one, some, or all of the lipid metabolites measured in the sample(s) may be eicosanoids.
- eicosanoids are provided in Table 2, in Table 9 in Example 5, and in Table 10 in Example 5.
- Exemplary abbreviations for eicosanoids are indicated in Table 9. Table 2.
- the method may involve measuring the amount of more than one lipid metabolite, such as 2, 3, 4, 5, 10, 15, 20, or more lipid metabolites, which may include 2, 3, 4, 5, 10, 15, 20, or more fatty acid markers described herein and/or 2, 3,4, 5, 10, 15, 20, or more eicosanoid markers described herein.
- two or more lipid metabolites in Table 2 are measured.
- three or more lipid metabolites in Table 2 are measured.
- five or more lipid metabolites in Table 2 are measured.
- two or more lipid metabolites in Tables 9 and/or 10 are measured.
- three or more lipid metabolites in Tables 9 and/or 10 are measured. In some embodiments, five or more lipid metabolites in Tables 9 and/or 10 are measured. In some embodiments, two or more lipid metabolites in Table 1, Table 2, Table 7 (see Example 4, below), Table 8 (see Example 4, below), Table 9, and/or Table 10 are measured. In some embodiments, three or more lipid metabolites in Table 1, Table 2, Table 7, Table 8, Table 9, and/or Table 10 are measured. In some embodiments, five or more lipid metabolites in Table 1, Table 2, Table 7, Table 8, Table 9, and/or Table 10 are measured. In some embodiments, two or more lipid metabolites in Table 7, Table 8, and/or Table 10 are measured. In some embodiments, three or more lipid metabolites in Table 7, Table 8, and/or Table 10 are measured. In some embodiments, five or more lipid metabolites in Table 7, Table 8, and/or Table 10 are measured.
- one or more lipid metabolites are selected from the group consisting of PGB2; PGE2; PGF2 ⁇ ; 15-keto-PGF2 ⁇ ; 5-HETE; 8-HETE; 9-HETE;11-HETE; 12-HETE; 12-HEPE; 11, 12-EpETrE; 8,9-DiHETrE. 15-HETE; PGA2M; 6-keto-PGF1 ⁇ ; 11-DTXB2; 12,13-DiHOME; 9, 10-EpOME; 12, 13-EpOME; and 19,20-DiHDPA.
- the following eicosanoids are positively associated with NASH : PGB2; PGE2; PGF2 ⁇ ; 15-keto-PGF2 ⁇ ; 5-HETE; 8-HETE; 9-HETE; 11-HETE; 12-HETE; 12-HEPE; 11, 12-EpETrE; 8,9-DiHETrE; and 15-HETE.
- 15-HETE is positively associated with steatosis and/or NAFLD.
- the following eicosanoids are negatively associated with steatosis and/or NAFLD: PGA2M; 6- keto-PGF1 ⁇ ; 11-DTXB2; 12,13-DiHOME; 9, 10-EpOME; 12, 13-EpOME; and 19, 20-DiHDPA.
- the eicosanoid 19, 20-DiHDPA is negatively associated with NASH.
- the method is a method of diagnosing NASH in a subject, comprising not only determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject, but also the step of determining the level of an eicosanoid in a body fluid from the subject. In some embodiments, a higher than normal level of the eicosanoid is indicative of NASH.
- the eicosanoid is selected from the group consisting of 15-HETE; PGB2; PGE2; PGF2 ⁇ ; 15-keto-PGF2 ⁇ ; 5-HETE; 8-HETE; 9-HETE; 11-HETE; 12- HETE; 12-HEPE; 11,12-EpETrE; and 8,9-DiHETrE.
- the amounts of the eicosanoids are determined from a blood, serum, plasma, or isolated lipoprotein fraction sample.
- the invention further provides, in some embodiments, methods in which not only the amount of one or more lipid metabolites are determined in a sample, but also the amount of one or more additional biomarkers is determined.
- biomarkers may aid the diagnosis of steatosis, NAFLD and NASH:
- Body fluid and cellular samples may be used to measure these additional biomarkers.
- cellular samples include, but are not limited to, lymphocytes and macrophages.
- Table 3 List of Acylcarnitines L-Carnitine Butyrobetaine Acetyl carnitine Propionyl carnitine Butyryl carnitine Hexanoyl carnitine Valeryl carnitine Octanoyl carnitine Decanoyl carnitine Myristoyl carnitine Palmitoyl carnitine stearoyl carnitine Oleoyl carnitine Linoleoyl camitine Arachidoyl carnitine Dodecanoyl carnitine Table 4.
- biomarkers may aid in the diagnosis of NASH as distinct from NAFLD:
- Body fluid and cellular samples may be used to measure the additional markers.
- cellular samples include, but are not limited to, lymphocytes and macrophages.
- Measurements of the amounts of one or more of these additional biomarkers may be used in the methods of the invention, in addition to measurement of a lipid metabolite.
- the amount of one of the biomarkers is measured in a sample from the subject.
- the amounts of two of the biomarkers are measured in a sample from the subject.
- 3, 4, 5, 6, 7, 8, 10, 12, 15, 20, or more of the biomarkers may be measured in a sample from the subject.
- the methods of the invention may be used to diagnose NAFLD.
- the methods may also be used to assess the severity of a liver disorder, monitor a liver disorder, and/or assess the progression or regression of a liver disorder.
- the methods comprise comparing the amounts(s) of one or more lipid metabolites to one or more references.
- a reference represents the normal level of the lipid metabolite.
- a reference is an amount of the lipid metabolite previously measure for the same subject.
- the reference is a relative amount of the one or more fatty acids to total fatty acid content in the triglycerides in a sample from a body fluid previously obtained from the subject.
- the reference represents the relative amount of the one or more fatty acids to total fatty acid content in the triglycerides found in one or more samples from a body fluid of one or more subjects having normal livers.
- a method of diagnosis may comprise determining a relative amount of one or more fatty acids to total fatty acid content in the lipids of one or more lipid classes in a sample from a body fluid of the subject, and correlating that amount with the presence of the liver disorder.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is greater than the reference, hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH is indicated.
- the method may further comprise the step of comparing the relative amount to a reference, wherein if the relative amount is less than the reference, hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH is indicated.
- the severity of the liver disorder may be measured, wherein the relative amount indicates the severity of the liver disorder. Additionally, the relative amount indicates the current state of the liver, and thus a liver disorder may be monitored and/or the progression or regression of the disorder assessed.
- the relative amount may be measured at two or more time points. In some embodiments, the relative amount may be measured at 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 20, or more time points. Each time point may be separated by one or more hours, days, weeks, or months. By measuring the relative amount at more than one time point, the clinician may assess a subject's response to treatment.
- the relative amount may be compared to a reference. In some embodiments, if the relative amount is greater than the reference, hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH is indicated. In some embodiments, if the relative amount is less than the reference, hepatic impairment, hepatic steatosis, NAFLD, steatohepatitis, or NASH is indicated. The difference between the relative amount and the reference may also be used to indicate severity. For example, as the relative amount becomes increasingly greater than the reference, increasing severity of disease is indicated. Or, for example, as the relative amount becomes increasingly less than the reference, increasing severity of disease is indicated.
- Exemplary references may be based on the amount(s) of a lipid metabolite(s) from, but not limited to, individuals with normal livers, individuals with hepatic impairment, individuals with steatosis, individuals with NAFLD, individuals with steatohepatitis, individuals with NASH, individuals with cirrhosis, and/or individuals with fibrosis.
- the reference may also be based on individuals with a liver disorder resulting from a particular cause, for example, one or more of those found below.
- the reference may also be based on samples previously obtained from the subject, for example, before the liver disorder developed, before treatment began, after treatment was ended, and/or at different time points during treatment.
- the reference is the relative amount of one or more fatty acids to total fatty acid content in one or more lipid classes in one or more samples of a body fluid previously obtained from the subject. In some embodiments, the reference represents the relative amount of one or more fatty acids to total fatty acid content in one or more lipid classes in one or more samples of a body fluid of one or more subjects having normal livers.
- the subject is a mammal. In some embodiments, the mammal is a primate. In some embodiments, the subject is a human.
- the method is a method of monitoring a liver disorder that is used to determine the subject's response to treatment.
- fatty acid liver disorders that may benefit from the methods disclosed herein may be caused by a variety of factors.
- Non-limiting examples include: hepatitis; steatosis induced by viral or non-viral infectious agents, such as yellow fever, HIV, HBV, and HCV; drug-induced steatosis, such as by tamoxifen, uncoupling protein inhibitors, Isoniazid, Rifampicin, fibrates, and peroxisome proliferator-activated receptor (PPAR) agonists; metabolic causes, such as obesity, polycystic ovary syndrome (PCOS), diabetes, insulin resistance, and metabolic disorder; alcohol-based causes such as alcoholic fatty liver disease and alcoholic steatohepatitis; inborn errors of metabolism or genetic alterations, such as citrin deficiency, hemochromatosis, and hyperferritinemia; toxin-induced causes, such as toxin- induced steatosis or toxin-induced steatohepatitis,
- the liver disorder is associated with one or more conditions selected from the group consisting of: hepatitis, HIV infection, HBV infection, HCV infection, viral-induced steatosis, steatosis induced by a non-viral infectious agent, drug-induced steatosis, obesity, polycystic ovary syndrome (PCOS), diabetes, insulin resistance, metabolic disorder, alcoholic fatty liver disease, alcoholic steatohepatitis, an inborn error of metabolism, a genetic alteration, toxin-induced steatosis, toxin-induced steatohepatitis, malnutrition, impaired nutrient absorption, celiac disease, lipodystrophy, bariatric surgery, and a liver transplant.
- PCOS polycystic ovary syndrome
- the diagnostic methods may also be used for the assessment of liver grafts, suitability of individuals for liver graft donation, evaluation before bariatric surgery, evaluation of bariatric surgery patients to assess response to surgery, and evaluation of weight loss patients.
- Assays for lipid metabolite content may be performed on a body fluid sample.
- the amounts of the lipid metabolites are determined from sample(s) selected from the group consisting of blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid.
- the assays may be performed on whole blood, plasma, serum, or isolated lipoprotein fractions.
- the sample(s) are plasma or serum.
- Assays for the additional biomarkers may be performed on a body fluid or a cellular sample.
- multiple different lipid metabolites are measured in the same sample. In other embodiments, each of multiple lipid metabolites are measured from a different sample. If multiple samples are used, the samples may be from the same or different body fluids of the subject.
- the lipid metabolites and other biomarkers may readily be isolated and/or quantified by methods known to those of skill in the art, including, but not limited to, methods utilizing: mass spectrometry (MS), high performance liquid chromatography (HPLC), isocratic HPLC, gradient HPLC, normal phase chromatography, reverse phase HPLC, size exclusion chromatography, ion exchange chromatography, capillary electrophoresis, microfluidics, chromatography, gas chromatography (GC), thin-layer chromatography (TLC), immobilized metal ion affinity chromatography (IMAC), affinity chromatography, immunoassays, and/or colorimetric assays.
- MS mass spectrometry
- HPLC high performance liquid chromatography
- HPLC high performance liquid chromatography
- isocratic HPLC gradient HPLC
- normal phase chromatography normal phase chromatography
- reverse phase HPLC reverse phase HPLC
- size exclusion chromatography size exclusion chromatography
- ion exchange chromatography ca
- the methods of the invention utilize an immunoassay to determine lipid metabolite content. In some embodiments, the methods of the invention utilize MS to determine the concentration of a biomarker. In some embodiments, the methods of the invention utilize an immunoassay to determine the concentration of a biomarker.
- CE Zinellu A, et al. Assay for the simultaneous determination of guanidinoacetic acid, creatinine and creatine in plasma and urine by capillary electrophoresis UV-detection. J Sep Sci. 2006 Mar; 29(5):704- 8 ; Jabeen R, et al. Capillary electrophoresis and the clinical laboratory. Electrophoresis. 2006 May 23 ; Gao P, et al.
- the TrueMass® analytical platform may also be used for the methods of the invention.
- TrueMass® is an analytical platform that may be used to get quantitative data from serum or plasma on approximately 400 individual metabolites involved in structural and energetic lipid metabolism such as triglyceride, cholesterol ester and phospholipid metabolism. This platform is useful in profiling diseases as structural and energetic lipids are central components of metabolism and integrated into virtually every biological process in the body.
- a data set for a plasma or serum sample comprises the quantitative measurement of free cholesterol and the following fatty acids from phosphatidylcholines, phosphatidylethanolamines, lyso-phosphatidylcholines, triglycerides, diglycerides, free fatty acids, and cholesterol esters: 14:0, 15:0, 16:0, 18:0, 20:0, 22:0, 24:0, 14:1n5, 16:1n7, t16:1n7, 18:1n9, t18:1n9, 18:1n7, 18:2n6, t18:2n6, 18:3n6, 18:3n3, 18:4n3, 20:1n9, 20:2n6, 20:3n9, 20:3n6, 20:4n6, 20:3n3, 20:4n3, 20:5n3, 22:1n9, 22:2n6, 22:4n6, 22:5n3, 22:6n3, 24:1n9, 24:6n3 and plasmalog
- Non-limiting examples of suitable methods may also be found in: U.S. Pat. Publication No. 2004/0143461 and PCT Publication No. WO 03/005628 , titled "Generating, Viewing, Interpreting, and Utilizing a Quantitative Database of Metabolites”; Stanton, B. et al. Interaction of estrogen and 2,3,7,8- tetracholorodibenzo-p-dioxin (TCDD) with hepatic fatty acid synthesis and metabolism of male chickens (Gallus domesticus). Comp. Biochem. and Physiology Part C 129 (2001) 137-150 ; Watkins, S.M. et al.
- the method may include the following steps: extraction, lipid class separation, preparation of fatty acid methyl esters, and fatty acid and sterol separation and quantification.
- a non-limiting exemplary method includes the following steps: (1) Extractions: The lipids from 200 ⁇ L of plasma will be extracted using a modified Folch extraction in chloroform :methanol (2:1 v/v) ( Folch, J., M. Lees, et al. (1957). "A simple method for the isolation and purification of total lipides from animal tissues.” J Biol Chem 226(1):497-509 ). Each extraction is performed in the presence of a panel of quantitative authentic internal standards. Extracted lipids are concentrated and prepared for separation by HPLC.
- Lipid class separation Individual lipid classes are separated from the extract by HPLC using a variety of methods. Each separated lipid class is collected and dried under nitrogen in preparation for trans-esterification.
- Preparation of fatty acid methyl esters Lipid classes are trans-esterified in 3 N methanolic HCl in a sealed vial under a nitrogen atmosphere at 100°C for 45 min. The resulting fatty acid methyl esters are extracted from the mixture with hexane and prepared for automatic injection for gas chromatography by sealing the hexane extracts under nitrogen.
- Fatty acid and sterol separation and quantification Fatty acid methyl esters are separated and quantified by capillary gas chromatography using a gas chromatograph (Hewlett-Packard model 6890, Wilmington, DE) equipped with a 30 m DB-225MS capillary column (J&W Scientific, Folsom, CA) and a flame-ionization detector.
- a gas chromatograph Hewlett-Packard model 6890, Wilmington, DE
- DB-225MS capillary column J&W Scientific, Folsom, CA
- Surrogate or internal standards may be used in quantifying the lipid metabolites.
- Surrogate standards are known in the art. Non-limiting exemplary surrogate standards are described at, inter alia, pages 16-17 and 25-31 of PCT Publication No. WO 03/005628 , titled "Generating, Viewing, Interpreting, and Utilizing a Quantitative Database of Metabolites", and in U.S. Patent Publication No. US 2004/0143461 . Non-limiting exemplary surrogate standards are also provided below in Table 5. Table 5.
- kits for practicing the methods of the invention include (a) one or more reagents for measuring the amount of one or more lipid metabolites; and (b) instructions for use.
- a kit may provide 1, 2, 3, 4, 5, 10, 15, 20, or more reagents for measuring the amount of 1, 2, 3, 4, 5, 10, 15, 20, or more lipid metabolites.
- the kit may further provide one or more reagents for measuring one or more additional biomarkers, such as those disclosed above, and in Tables 2-4.
- the kit includes one or more reagents for use in an immunoassay.
- the kit includes one or more reagents for use in an MS assay.
- the reagent is an antibody. Methods of making antibodies are known to those of ordinary skill in the art.
- kits for use in each of the methods described herein comprising (a) an antibody to a lipid metabolite; and (b) instructions for use.
- the kit further comprises: (c) a second antibody to a second lipid metabolite.
- the kit further comprises (d) a third antibody to a third lipid metabolite.
- the first, second, and/or third lipid metabolite is a fatty acid.
- the first data set comprised forty-nine (49) liver biopsy samples, which were profiled to determine hepatic triglyceride composition and correlation with hepatic triglyceride concentrations.
- liver biopsy samples were eight (8) subjects graded as NASH, six (6) subjects graded as NAFLD, and thirty-five (35) normal samples as assessed by a pathological examination of the tissue.
- These 49 liver samples were collected from males and females of diverse races (white, black, and undefined).
- Nine of the subjects with normal liver provided matching plasma samples. These samples were used to provide a correlation between liver triglyceride content and plasma lipid metabolites.
- a second data set included serum samples from eight subjects with hepatic impairment and eight normal (by liver biopsy) individuals. This data set was used to confirm the findings from the liver biopsy analysis.
- lipids from plasma and tissues were extracted in the presence of authentic internal standards by the method of Folch et al. ( Folch, J., et al. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:497-509 ) using chloroform-methanol (2:1, v/v). Plasma 200 ⁇ l was used for each analysis. Individual lipid classes within each extract were separated by preparative thin-layer chromatography as described in Watkins, S. M., et al. 2001. Unique phospholipid metabolism in mouse heart in response to dietary docosahexaenoic or ⁇ alpha ⁇ -linolenic acids. Lipids. 36: 247-254 .
- Authentic lipid class standard compounds were spotted on the two outside lanes of the thin-layer chromatography plate to enable localization of the sample lipid classes.
- Each lipid fraction was scraped from the plate and trans-esterified in 3 N methanolic-HCl in a sealed vial under a nitrogen atmosphere at 100°C for 45 min.
- the resulting fatty acid methyl esters were extracted from the mixture with hexane containing 0.05% butylated hydroxytoluene and prepared for gas chromatography by sealing the hexane extracts under nitrogen.
- Fatty acid methyl esters were separated and quantified by capillary gas chromatography using a gas chromatograph (Hewlett-Packard model 6890, Wilmington, DE) equipped with a 30 m DB-225MS capillary column (J&W Scientific, Folsom, CA) and a flame-ionization detector as described in Watkins, S. M., et al. 2001.
- a gas chromatograph Hewlett-Packard model 6890, Wilmington, DE
- J&W Scientific, Folsom, CA flame-ionization detector
- the analytical software (Atlas 2003; Thermo Electron Corporation) identified each analyte lipid metabolite of interest based on the reference standard and generated a raw area.
- the raw area, peak shape parameters and the response factor for each analyte were exported to an information management system, where an integration algorithm was used to generate the corrected areas for each analyte of interest.
- Quantitative data were calculated by taking the ratio of the area of the analyte peak to the area of the appropriate surrogate. This ratio was multiplied by the concentration of the surrogate in the original sample to generate data in a microgram per gram of sample format.
- Each analyte was then divided by its molecular weight and multiplied by 1000 to calculate the nMoles of analyte per gram of sample.
- Mole percentage data for each lipid class was calculated by dividing the concentration of each fatty acid by the sum of the concentrations of fatty acids within that class.
- Untransformed mole percentage data were used to correlate with hepatic triglyceride content and was also used for the confirmation of results in the hepatic impairment study.
- Pearson's correlation coefficient was used to evaluate the relationship of each metabolite with total hepatic triglycerides.
- the metabolites in Table 6 were correlated with total hepatic triglycerides ( ⁇ ⁇ 0.2) and were compared with differences observed in serum between hepatic impaired and normal individuals. Those metabolites that had an opposite effect in hepatic impaired individuals (by an unpaired Student's t-Test on two groups: normal and hepatic impaired) were not included in Table 6.
- blood plasma fatty acid composition of triglyceride and phosphatidylcholine were an accurate indicator of the liver fatty acid composition of triglycerides and phosphatidylcholine, respectively.
- blood plasma based measurements of fatty acids may indicate the quantitative amount of triglyceride in the liver (steatosis), provided the compositional data in liver is well-correlated with steatosis.
- ROC Receiver Operating Characteristic
- the first data set was used in this experiment.
- the liver samples of 49 subjects were graded for degree of hepatic steatosis and inflammation.
- Six subjects were graded as NAFLD and eight subjects were graded as NASH. All other samples were presumed normal.
- the samples were profiled using TrueMass ® technology; many metabolites were found to correlate either positively or negatively with total hepatic triglyceride concentrations.
- monounsaturated fatty acids were generally positively correlated with steatosis and essential fatty acids were generally negatively correlated with steatosis.
- One example of a metabolite that was well-correlated with total hepatic triglycerides was the fatty acid 20:4n6, expressed as a percentage of all fatty acids present in triglycerides ( Fig. 3 ).
- Figure 3 shows the relationship between hepatic triglyceride concentrations (nmoles/g) and the relative proportion of 20:4n6 in hepatic triglycerides (expressed as a mole percentage of total triglyceride fatty acids).
- the relative proportion of TG20:4n6 was an excellent predictor of the total concentration of triglycerides in liver.
- several normal samples exhibited NAFLD-levels of triglycerides, and the relative proportion of 20:4n6 remained an excellent predictor of total triglyceride concentrations.
- the metabolite markers of NAFLD and NASH in Table 6 were selected based on their observed and/or predicted correlation with the total triglyceride content of liver. Additionally, these markers shown some correlation useful in classifying all 16 subjects tested with normal liver function or hepatic impairment. Table 6.
- NASH NASH, NAFLD, and normal control plasma samples were collected to examine the differences in the lipid composition in plasma. There were 30 NASH patients, 7 NAFLD patients, and 12 normal controls.
- Lipid metabolites were quantified from fasted plasma, serum and liver samples. Lipids measured included cholesterol, cholesterol esters (CE), diglycerides (DG), free cholesterol (FS), free fatty acids (FA), lysophosphatidylcholine (LY), phosphatidylcholine (PC), phosphatidylethanolamine (PE) and triglycerides (TG).
- CE cholesterol esters
- DG diglycerides
- FS free cholesterol
- FA free fatty acids
- LY lysophosphatidylcholine
- PC phosphatidylcholine
- PE phosphatidylethanolamine
- TG triglycerides
- fatty acid components were quantified as a proportion of total fatty acids within the lipid class: 14:0, 15:0, 16:0, 18:0, 20:0, 22:0, 24:0, 14: 1n5, 16:1n7, 18:1n7, 18:1n9, 20:1n9, 20:3n9, 22:1n9, 24:1n9, 18:2n6, 18:3n6, 20:2n6, 20:3n6, 20:4n6, 22:2n6, 22:4n6, 22:5n6, 18:3n3, 18:4n3, 20:3n3, 20:4n3, 20:5n3, 22:5n3, 22:6n3, 24:6n3, plasmalogen derivatives of 16:0, 18:0, 18:1n7 and 18:1n9, t16:1n7 t18:1n9 t18:2n6.
- LC indicates the value shown is the total concentration of the lipid class expressed as nMoles per gram of serum or plasma.
- the abbreviation PC18:2n6 indicates the percentage of plasma or serum phosphatidylcholine comprised of linoleic acid (18:2n6)
- the term TGLC indicates the absolute amount (in nMoles per gram) of triglyceride present in plasma or serum.
- the lipids from the sample were extracted in the presence of authentic surrogate standards for each lipid class by a liquid:liquid extraction, creating a lipid extract.
- the mass of the sample and surrogate were recorded at this step in order to accurately determine the amount of material being analyzed.
- the mass of the sample and the surrogate standards were used to calculate the quantitative amount of each fatty acid in each lipid class.
- the neutral and phospholipid classes were separated from one another via a solid phase extraction with a Varian Vac Elut 20 vacuum manifold and Supelco LC-SI silica packed SPE cartridges. Once these extracts were prepared, the neutral lipid classes were separated by preparative thin layer chromatography on silica gel G-60 TLC plates. The phospholipid classes were separated via high performance liquid chromatography on an Agilent 1100 Series HPLC, with a Phenomenex Sperex 5u OH Diol column (250 x 4.6mm, 5 micron) and a SEDEX 75 evaporative light scattering detector.
- lipid class was trans-esterified with 1% sulfuric acid in methanol, resulting in the formation of fatty acid methyl esters (FAMEs).
- FAMEs fatty acid methyl esters
- the FAME mixture for each class was separated and quantified by capillary gas chromatography (GC) on an Agilent GC6890, with a J&W Scientific HP-88 fused silica capillary column (30m x 25um, 0.2 um film) and a flame-ionization detector.
- Tables 7 and 8 show markers significantly associated with NASH and NAFLD, respectively. Most lipid classes in NASH and NAFLD subjects did not differ significantly from normal. Phosphatidylethanolamine and phosphatidylcholine were significantly decreased in NASH relative to normal (p-values from t-test: 0.001, 0.021). Phosphatidylcholine and lysophosphatidylcholine were significantly decreased in NAFLD relative to normal (p-values from t-test: 0.05, 0.042). Very similar results were obtained from the non-parametric Wilcoxon test.
- Omega 3 fatty acids were decreased, particularly DHA, in NASH subjects relative normal controls. Decreases in DHA were seen in NASH relative to normal controls both quantitatively and compositionally in CE, PC and PE. DHA was significantly decreased in NASH in FA, LY, and TG only compositionally. 18:3n3 was significantly decreased in PC both quantitatively and compositionally, while it was only significantly reduced compositionally in free fatty acids. 22:5n3 was significantly increased compositionally in PC in NASH and NAFLD relative to normal subjects.
- NASH markers (significant in t test at .1, p value is shown in parentheses) Lipid Class Increased from Normal Decreased from Normal Diacylglycerol DG20:3n6 (0.0868) DG22:5n6 (0.0418) Triacylglycerol TG18:1n7 (0.0709) TG18:3n3 (0.0934) TG20:3n6 (0.0025) TG20:3n9 (0.0999) TG22:6n3 (0.0364) TG24:0 (0.0602) Free fatty acid FA18:1n7 (0.0015) FA16:0 (0.0448) FA18:1n9 (0.0018) FA18:3n3 (0.0051) FA20:3n6 (0.0123) FA22:6n3 (0.0018) Phospholipids PC18:0 (0.004) PCLC (0.001) PC18:3n6 (0.0181) PC18:3n3 (0.0378) PC20:3n6 (0.0001) PC22:6n3 (0.0405) PC
- Example 3 Contrary to what was identified in Example 3, in this particular study, the following metabolites were not found to be positively associated with steatosis: PC 20:2n6; PC18:1n7; and CE22:6n3. Furthermore, in this study, contrary to what was identified in Example 3, the following metabolites were not found to be negatively associated with steatosis: TG20:3n6; TG22:5n3; and PC22:5n3.
- the eicosanoids from 250 ⁇ L of plasma or serum were extracted using protein precipitation and filtering prior to loading on an LC/MS. Twenty microliters of a mixture of deuterated surrogates for quantitation was added to each sample and thoroughly mixed. To each plasma/serum sample 10 ⁇ L antioxidant solution (0.2mg/mL BHT.EDTA in 50:50 MeOH:H2O) was added and thoroughly mixed. Protein precipitation was carried out by adding I mL methanol to each sample followed by mixing. The samples were centrifuged at - 4°C and 17000g for 10 minutes. The supernatants were dried under nitrogen for 2 hours at 10psi.
- Dried samples were reconstituted with 60ul mcthanol:deionized water (50:50). After mixing, samples were transferred to silanized autosampler inserts for LC/MSMS analysis. The samples were injected onto an Agilent Stable Bond C18 column (150x2.1mm, 1.8 micron) connected to an Applied Biosystems 4000 QTRAP. The analytes were ionized via negative electrospray and the mass spectrometer was operated in the tandem MS mode.
- Quantitative data (pMoles per gram of plasma) were evaluated for markers of NAFLD and NASH. Quantitative data were not transformed for the analysis. Metabolites not detected in more than 30% of subjects were not included in the statistical analysis. Two-tailed t-tests were used to compare the groups (NASH vs. Normals, and NAFLD vs. Normals).
- Table 10 shows the eicosanoid metabolites that were significantly associated with NASH and NAFLD.
- the NAFLD group have significantly higher 13,14-dihydro-15-keto Prostaglandin A 2 , 11-dehydro-Thromboxane B 2 , and 12,13-Dihydroxyoctadecenoic acid. 19,20-Dihydoxydocosapentaenoic acid was significantly decreased according to the t-test but did not reach significance by the Wilcoxon test.
- the NASH group had significantly higher Prostaglandin E 2 , 15-keto-Prostaglandin F 2 ⁇ , and Leukotriene D 4 as assessed by the Wilcoxon test, but did not reach significance by t-test.
- HETE's including 5-HETE, 8-HETE, 9-HETE, 11-HETE, 12-HETE, and 15-HETE, were significantly increased in NASH over normal in both tests.
- 11-HETE and 15-HETE were linearly anti-correlated, but more strongly anti-correlated on a log scale, with DHA in a few lipid classes. Table 10.
- NASH and NAFLD markers (significant in t test at.
- NASH NAFLD Increased Decreased Increased Decreased PGB 2 (0.0815) 19,20-DiHDPA (0.063) 15-HETE (0.0937) PGA 2 M (0.0296) PGE 2 (0.0627) 6-keto-PGF 1 ⁇ (0.0896) PGF 2 ⁇ (0.0542) 11-DTXB 2 (0.0027) 15-keto-PGF 2 ⁇ (0.0603) 12,13-DiHOME (0.009) 5-HETE (0.019) 9,10-EpOME (0.0785) 8-HETE (0.0012) 12,13-EpOME (0.0977) 9-HETE (0.0031) 19,20-DiHDPA (0.0297) 11-HETE (0.0001) 8-iso-PGF 2 ⁇ (0.0976) 12-HETE (0.0206) 15-HETE (0.0001) 12-HEPE (0.0902) 11,12-EpETrE (0.0744) 8,9-DiHETrE (0.0004)
- Diagnostics for NASH can be built either from the described marker metabolites directly or from simple combinations of these markers. As each diagnostic application requires unique performance characteristics, metabolite concentrations can be combined into simple algorithms to provide the sensitivity and specificity required for a particular desired test.
- Example 4 and Example 5 were used to develop classifiers for distinguishing NASH from NAFLD and Normal subjects.
- Linear combinations of metabolite pairs were evaluated for their ability to classify NASH versus NAFLD using a receiver operator curve (ROC).
- Performance characteristics evaluated in this experiment included the area under the ROC curve (ROC AUC), the sensitivity and the specificity of the test. Examples of combinations that provided overall sensitivity and specificity (Combination 1), high sensitivity with less specificity (Combinations 2 and 3), and high specificity with less sensitivity (Combinations 4 and 5) are shown in Table 11 below.
- the desired test performance will depend on the application (for instance if a subject is to undergo an invasive procedure on the basis of the test, it may be most useful to ensure a high-degree of specificity).
- the performance of the test can be modulated by choosing the individual metabolites components of the algorithm and the threshold (critical value) for classification.
- the metabolites chosen for inclusion in the algorithm may be any of the eicosanoids or fatty acid markers described herein or any of the following acylcarnitines, sterols, bile acids or oxysterols: Carnitine Metabolites and Acylcarnitines: L-Carnitine, g-Butyrobetaine; Trimethyllysine; Acetylcarnitine; Propionylcarnitine; Butyrylcarnitine; Valerylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Dodecanoylcarnitine; Myristoylcarnitine; Palmitoyicarnitine; Stearoylcarnitine; Oleoylcamitine; Linoleoylcarnitine.
- Sterols, Bile Acids and Oxysterols Cholesterol; 7-Dehydrocholesterol; Desmosterol; Lanosterol; Lathasterol; Cholestanol; Coprostanol; b-Sitosterol; Campesterol; Stigmasterol; 4-Cholesten-7a-ol-3-one; 7a-Hydroxycholesterol; 27-Hydroxycholesterol; 25-Hydroxycholesterol; 24S-Hydroxycholesterol; 4b-hydroxycholesterol; Cholic acid; Chenodeoxycholic acid; Deoxycholic acid; Lithocholic acid; Glycocholic acid; Glycochenodeoxycholic acid; Glycodeoxycholic acid; Glycolithocholic acid; Taurocholic acid; Taurochenodeoxycholic acid; Taurodeoxycholic acid; Taurolithocholic acid; Ursodeoxycholic acid; Glycoursodeoxycholic acid.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
- Verfahren zur Diagnose oder Kontrolle von nichtalkoholischer Fettleber (Non-Alcoholic Fatty Liver Disease, NAFLD) bei einem Subjekt, bei dem man:(A) die Menge eines oder mehrerer Lipidmetaboliten in einer oder mehreren Plasmaproben von dem Subjekt bestimmt, wobei:die Lipidmetaboliten PC18:3n6, PC20:3n6, CE18:3n6, PC20:4n3, PC18:0, PC22:5n3, CE20:3n6, TG20:3n6, TG22:5n3, LYLC, LY18:0, LY20:3n6, FA18:1n9, FA20:3n6 und/oder 15-HETE positiv mit NAFLD assoziiert sind unddie Lipidmetaboliten TG22:2n6, PC18:2n6, PC20:2n6, SM16:0, PCLC, PC18:1n7, LY18:1n7, LY18:2n6, PGA2M, 6-keto-PGF1α, 11-DTXB2, 12,13-DiHOME, 9,10-EpOME, 12,13-EpOME und/oder 19,20-DiHDPA negativ mit NAFLD assoziiert sind, und(B) die Menge(n) des einen oder der mehreren Lipidmetaboliten mit dem Vorliegen von NAFLD korreliert.
- Verfahren nach Anspruch 1, wobei das Verfahren Folgendes umfasst:das Bestimmen einer relativen Menge einer oder mehrerer Fettsäuren, bezogen auf den Gesamtfettsäuregehalt, in den Lipiden des einen oder der mehreren Lipidmetaboliten in der Plasmaprobe von dem Subjekt unddas Korrelieren der relativen Menge(n) mit dem Vorliegen von NAFLD.
- Verfahren nach einem der vorhergehenden Ansprüche, wobei die Menge(n) der einen oder mehreren Fettsäuren in dem einen oder den mehreren Lipidmetaboliten die relative Menge(n) der einen oder mehreren Fettsäuren, bezogen auf den Gesamtfettsäuregehalt, in den Lipiden von einer oder mehreren Lipidklassen in einer oder mehreren Proben ist/sind.
- Verfahren nach einem der vorhergehenden Ansprüche, bei dem man weiterhin die Menge(n) des einen oder der mehreren Lipidmetaboliten mit einem oder mehreren Vergleichswerten vergleicht.
- Verfahren nach einem der vorhergehenden Ansprüche, bei dem man die Mengen von zwei oder mehr der Lipidmetaboliten bestimmt.
- Verfahren nach einem der vorhergehenden Ansprüche, wobei man das Kontrollverfahren anwendet, um die Reaktion des Subjekts auf eine Behandlung festzustellen.
- Verfahren nach einem der Ansprüche 1-5, bei dem das Kontrollverfahren das Einschätzen des Fortschreitens von NAFLD umfasst.
- Verfahren nach einem der vorhergehenden Ansprüche, wobei das Subjekt ein Mensch ist.
- Verfahren nach einem der vorhergehenden Ansprüche, wobei es sich bei dem Subjekt um einen Kandidaten für die Spende eines Lebertransplantats handelt, das Subjekt auf eine Eignung für einen bariatrischen Eingriff untersucht wird oder das Subjekt sich einem bariatrischen Eingriff unterzogen hat.
- Verfahren nach einem der vorhergehenden Ansprüche, bei dem man zur Quantifizierung der Wirkung der einzelnen Lipidmetaboliten von dem einen oder den mehreren Lipidmetaboliten mathematische Formeln oder Modelle anwendet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17194611.4A EP3285072B1 (de) | 2006-08-08 | 2007-08-08 | Marker von nichtalkoholischer fettlebererkrankung (nafld) und nichtalkoholischer steatohepatitis (nash) sowie verfahren zur verwendung davon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83655506P | 2006-08-08 | 2006-08-08 | |
EP07836680.4A EP2057473B1 (de) | 2006-08-08 | 2007-08-08 | Marker für nichtalkoholische fettlebererkrankung (nafld) und nichtalkoholische steatohepatitis (nash) sowie anwendungsverfahren |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07836680.4A Division EP2057473B1 (de) | 2006-08-08 | 2007-08-08 | Marker für nichtalkoholische fettlebererkrankung (nafld) und nichtalkoholische steatohepatitis (nash) sowie anwendungsverfahren |
EP07836680.4A Division-Into EP2057473B1 (de) | 2006-08-08 | 2007-08-08 | Marker für nichtalkoholische fettlebererkrankung (nafld) und nichtalkoholische steatohepatitis (nash) sowie anwendungsverfahren |
EP07836680.4 Division | 2007-08-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17194611.4A Division EP3285072B1 (de) | 2006-08-08 | 2007-08-08 | Marker von nichtalkoholischer fettlebererkrankung (nafld) und nichtalkoholischer steatohepatitis (nash) sowie verfahren zur verwendung davon |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2607902A1 EP2607902A1 (de) | 2013-06-26 |
EP2607902B1 true EP2607902B1 (de) | 2017-10-04 |
Family
ID=39082612
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07836680.4A Active EP2057473B1 (de) | 2006-08-08 | 2007-08-08 | Marker für nichtalkoholische fettlebererkrankung (nafld) und nichtalkoholische steatohepatitis (nash) sowie anwendungsverfahren |
EP12196378.9A Active EP2607902B1 (de) | 2006-08-08 | 2007-08-08 | Marker für nicht alkoholische Fettlebererkrankung (NAFLD) und nicht alkoholische Steatohepatitis (NASH) sowie Anwendungsverfahren dafür |
EP17194611.4A Active EP3285072B1 (de) | 2006-08-08 | 2007-08-08 | Marker von nichtalkoholischer fettlebererkrankung (nafld) und nichtalkoholischer steatohepatitis (nash) sowie verfahren zur verwendung davon |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07836680.4A Active EP2057473B1 (de) | 2006-08-08 | 2007-08-08 | Marker für nichtalkoholische fettlebererkrankung (nafld) und nichtalkoholische steatohepatitis (nash) sowie anwendungsverfahren |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17194611.4A Active EP3285072B1 (de) | 2006-08-08 | 2007-08-08 | Marker von nichtalkoholischer fettlebererkrankung (nafld) und nichtalkoholischer steatohepatitis (nash) sowie verfahren zur verwendung davon |
Country Status (10)
Country | Link |
---|---|
US (2) | US20100233724A1 (de) |
EP (3) | EP2057473B1 (de) |
JP (1) | JP2010500566A (de) |
CN (1) | CN101523221A (de) |
AU (1) | AU2007284733A1 (de) |
BR (1) | BRPI0715402A2 (de) |
CA (1) | CA2662987A1 (de) |
ES (1) | ES2527438T3 (de) |
HK (1) | HK1131209A1 (de) |
WO (1) | WO2008021192A2 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156662A1 (en) | 2007-06-14 | 2008-12-24 | George Mason Intellectual Properties, Inc. | Methods of diagnosing non-alcoholic steatohepatitis (nash) |
WO2009059150A2 (en) * | 2007-11-02 | 2009-05-07 | Metabolon, Inc. | Biomarkers for fatty liver disease and methods using the same |
FI122252B (fi) * | 2008-01-04 | 2011-10-31 | Valio Oy | Koostumus maksa-aineenvaihdunnan parantamiseksi ja diagnostinen menetelmä |
US8597875B2 (en) | 2008-05-28 | 2013-12-03 | Basf Se | Method for diagnosing liver toxicity with sex specific biomarkers |
WO2009151125A1 (ja) * | 2008-06-13 | 2009-12-17 | 持田製薬株式会社 | 肝障害の診断及び治療 |
WO2010000835A1 (en) | 2008-07-03 | 2010-01-07 | One Way Liver Genomics, S.L. | Proteomic fingerprint for the diagnosis of non-alcoholic steatohepatitis (nash) and/or steatosis |
CA2727855A1 (en) * | 2008-07-15 | 2010-01-21 | Metanomics Health Gmbh | Means and methods diagnosing gastric bypass and conditions related thereto |
EP2157431A1 (de) | 2008-08-11 | 2010-02-24 | One Way Liver Genomics, S.L. | Verfahren zur NASH-Diagnose unter Verwendung von Stoffwechselprofilen |
JP5403581B2 (ja) * | 2008-09-02 | 2014-01-29 | 国立大学法人 岡山大学 | 5−heteを含有する抗hcv剤およびその利用 |
JP5322556B2 (ja) * | 2008-09-19 | 2013-10-23 | 株式会社Mcbi | 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法 |
ES2621838T3 (es) | 2008-11-18 | 2017-07-05 | Universite D'angers | Método in vitro no invasivo para la cuantificación de lesiones hepáticas |
US20170138965A1 (en) * | 2015-11-13 | 2017-05-18 | Nanoveson Llc | Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comormid Disease |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
US11835503B2 (en) * | 2009-05-28 | 2023-12-05 | The Cleveland Clinic Foundation | TMA-formation inhibitor treatment for elevated TMA-containing compound diseases |
EP2309276A1 (de) * | 2009-09-22 | 2011-04-13 | One Way Liver Genomics, S.L. | Verfahren zur Diagnose von nichtalkoholischer Steatohepatitis basierend auf einem metabolomischen Profil |
WO2011059721A1 (en) * | 2009-10-29 | 2011-05-19 | Tethys Bioscience, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
WO2011140093A2 (en) * | 2010-05-03 | 2011-11-10 | The Cleveland Clinic Foundation | Detection and monitoring of nonalcoholic fatty liver disease |
EP2385374B2 (de) * | 2010-05-05 | 2018-02-28 | Zora Biosciences OY | Lipidomik-Biomarker für Atherosklerose und kardiovaskuläre Erkrankung |
EP3273247A1 (de) | 2010-06-10 | 2018-01-24 | Metanomics Health GmbH | Methoden zur diagnose von krankheiten der leber |
JP5980900B2 (ja) * | 2011-04-08 | 2016-08-31 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
WO2012143514A1 (en) * | 2011-04-20 | 2012-10-26 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Method for the diagnosis of liver injury based on a metabolomic profile |
EP2810079A4 (de) * | 2012-01-31 | 2015-08-05 | Teknologian Tutkimuskeskus Vtt Oy | Verfahren zur bestimmung der leberfettmenge und verfahren zur diagnose von nafld |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
JP2016538288A (ja) | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
JP6680677B2 (ja) * | 2013-12-10 | 2020-04-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 肝疾患の鑑別診断 |
US20170184613A1 (en) * | 2014-05-23 | 2017-06-29 | Georgetown University | Exosome and lipid biomarkers for memory loss |
CN104280477B (zh) * | 2014-11-03 | 2016-03-30 | 天津中医药大学 | 内源性小分子物质在快速检测肝毒性方面的应用 |
MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
JP6783239B2 (ja) * | 2015-02-13 | 2020-11-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非アルコール性脂肪性肝疾患を特定するための方法及び組成物 |
EP3282256A4 (de) * | 2015-04-10 | 2019-03-06 | Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. | Verfahren zur unterscheidung des symptoms einer lebererkrankung |
EP3325094B1 (de) | 2015-07-21 | 2021-01-06 | Afimmune Limited | Zusammensetzungen mit 15(s)-hepe zur verwendung bei der sensibilisierung von krebszellen für die strahlentherapie |
BR122023026625A2 (pt) | 2015-12-18 | 2024-01-16 | Afimmune Limited | Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo |
WO2017167821A1 (en) * | 2016-03-29 | 2017-10-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lipid biomarkers and compositions |
JP7036805B2 (ja) * | 2016-05-29 | 2022-03-15 | 深▲じぇん▼市▲絵▼云生物科技有限公司 | 肝疾患関連バイオマーカーおよびその使用方法 |
WO2018007422A1 (en) | 2016-07-05 | 2018-01-11 | One Way Liver,S.L. | Identification of human non-alcoholic fatty liver disease (nafld) subtypes |
EP3267199A1 (de) | 2016-07-06 | 2018-01-10 | One Way Liver S.L. | Diagnostische methoden basierend auf lipidprofilen |
JP2016191718A (ja) * | 2016-07-27 | 2016-11-10 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
CN107952083B (zh) * | 2016-10-14 | 2021-12-03 | 复旦大学附属华山医院 | 脂代谢相关分子urg4或urgcp及其应用 |
US10548710B2 (en) | 2017-02-24 | 2020-02-04 | The Cleveland Clinic Foundation | Method and apparatus for time-differential deployment of an endovascular device within a body lumen |
CN110694071B (zh) * | 2017-08-21 | 2020-09-22 | 武汉大学 | Gpr31抑制剂在制备治疗心肌肥厚及相关疾病药物中的应用 |
BR112020004439A2 (pt) * | 2017-09-18 | 2020-10-06 | Genfit | diagnóstico não invasivo de doenças de fígado gorduroso não alcoólico, esteato-hepatite não alcoólica e/ou fibrose de fígado |
EP3502703A1 (de) | 2017-12-22 | 2019-06-26 | Metanomics Health GmbH | Verfahren zur beurteilung von nafld |
GB2618001B (en) * | 2018-02-20 | 2024-01-31 | Emulate Inc | Human microphysiological cell system for liver disease |
CN108932976A (zh) * | 2018-06-11 | 2018-12-04 | 西安医学院 | 一种非酒精性脂肪性肝病无创性诊断程序 |
JP6592638B1 (ja) * | 2018-08-30 | 2019-10-16 | 国立大学法人 東京大学 | 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー |
WO2020044497A1 (ja) * | 2018-08-30 | 2020-03-05 | 国立大学法人 東京大学 | Nafld又はnashの検出又はリスクの予測方法、nafld又はnashを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット |
WO2020066162A1 (ja) * | 2018-09-26 | 2020-04-02 | 株式会社島津製作所 | 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー |
WO2020073000A1 (en) * | 2018-10-05 | 2020-04-09 | The Regents Of The University Ofcalifornia | Methods and compositions for determination of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) |
KR102105880B1 (ko) * | 2018-10-26 | 2020-04-29 | 서울대학교병원 | 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법 |
JP6592628B1 (ja) * | 2019-03-12 | 2019-10-16 | 国立大学法人 東京大学 | 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー |
JP6592627B1 (ja) * | 2019-03-12 | 2019-10-16 | 国立大学法人 東京大学 | Nafld又はnashの検出又はリスクの予測方法、nafld又はnashを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット |
US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
CN112433012A (zh) * | 2020-11-23 | 2021-03-02 | 华南农业大学 | 一种鸡肉品质脂肪酸评价模型的构建方法及应用 |
DE102022131674A1 (de) | 2022-11-30 | 2024-06-06 | Universitätsklinikum Jena, Körperschaft des öffentlichen Rechts | Diagnose von Metabolischen Veränderungen der Leber mittels metabolischer Analyse von Erythrozyten durch Massenspektrometrie |
CN115876935B (zh) * | 2022-12-29 | 2023-11-14 | 大连博源医学科技有限公司 | 一种用于检测血液中11-脱氢血栓烷b2的液相色谱-串联质谱方法和试剂盒 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE386986T1 (de) | 2001-07-06 | 2008-03-15 | Lipomics Technologies Inc | Erzeugen, betrachten, interpretieren und verwenden einer quantitativen datenbank von metaboliten |
WO2003028271A2 (en) * | 2001-09-24 | 2003-04-03 | Lipomics Technologies, Inc. | Methods of using quantitative lipid metabolome data |
WO2003078574A2 (en) * | 2002-03-11 | 2003-09-25 | Lipomics Technologies, Inc. | Novel metabolic targets and markers |
EP1739431A4 (de) * | 2004-04-23 | 2008-10-15 | Ajinomoto Kk | Verfahren zur beurteilung nichtalkoholischer steatohepatitis |
EP1789806A2 (de) * | 2004-09-13 | 2007-05-30 | Lipomics Technologies, Inc. | Metabolitmarkierer zur gewichtsverwaltung |
EP2923699B1 (de) * | 2006-05-09 | 2018-06-20 | Genzyme Corporation | Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese |
-
2007
- 2007-08-08 EP EP07836680.4A patent/EP2057473B1/de active Active
- 2007-08-08 EP EP12196378.9A patent/EP2607902B1/de active Active
- 2007-08-08 BR BRPI0715402-0A2A patent/BRPI0715402A2/pt not_active IP Right Cessation
- 2007-08-08 EP EP17194611.4A patent/EP3285072B1/de active Active
- 2007-08-08 CN CNA2007800375689A patent/CN101523221A/zh active Pending
- 2007-08-08 JP JP2009523847A patent/JP2010500566A/ja active Pending
- 2007-08-08 AU AU2007284733A patent/AU2007284733A1/en not_active Abandoned
- 2007-08-08 ES ES07836680.4T patent/ES2527438T3/es active Active
- 2007-08-08 CA CA002662987A patent/CA2662987A1/en not_active Abandoned
- 2007-08-08 WO PCT/US2007/017726 patent/WO2008021192A2/en active Application Filing
- 2007-08-08 US US12/376,903 patent/US20100233724A1/en not_active Abandoned
-
2009
- 2009-11-12 HK HK09110580.6A patent/HK1131209A1/xx unknown
-
2019
- 2019-08-06 US US16/532,801 patent/US20200116743A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
EP3285072A1 (de) | 2018-02-21 |
HK1131209A1 (en) | 2010-01-15 |
BRPI0715402A2 (pt) | 2013-11-26 |
AU2007284733A1 (en) | 2008-02-21 |
US20100233724A1 (en) | 2010-09-16 |
WO2008021192A3 (en) | 2008-11-06 |
EP2057473A2 (de) | 2009-05-13 |
WO2008021192A2 (en) | 2008-02-21 |
EP2607902A1 (de) | 2013-06-26 |
CA2662987A1 (en) | 2008-02-21 |
EP2057473B1 (de) | 2014-11-12 |
ES2527438T3 (es) | 2015-01-26 |
EP3285072B1 (de) | 2020-04-15 |
US20200116743A1 (en) | 2020-04-16 |
EP2057473A4 (de) | 2009-09-02 |
CN101523221A (zh) | 2009-09-02 |
JP2010500566A (ja) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200116743A1 (en) | Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample | |
AU2008219700B2 (en) | Metabolic markers of diabetic conditions and methods of use thereof | |
US8216848B2 (en) | Means and method for diagnosing diabetes | |
JP2010519543A5 (de) | ||
CA2799032A1 (en) | Methods to diagnose liver diseases | |
AU2009259540A1 (en) | Means and methods for assessing liver toxicity | |
EP2828668A1 (de) | Hydroxy-sphingomyelin 22:1 als biomarker für gesundes altern | |
WO2013139579A1 (en) | 9-oxo-octadecadienoic acid (9-oxo-hode) as as biomarker for healthy ageing | |
EP2828666A1 (de) | P-cresolsulfat als biomarker für gesundes altern | |
EP2286245A2 (de) | Mittel und verfahren zur beurteilung erhöhter peroxisomproliferation | |
EP2828665A1 (de) | 1-o-alkyl-2-acylglycerophosphocholin (pc-o) 40:1 als biomarker für gesundes altern | |
Li et al. | Association of serum total fatty acids with type 2 diabetes | |
WO2020073000A1 (en) | Methods and compositions for determination of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) | |
EP2526426A1 (de) | Testverfahren für durch dyslipidämie gekennzeichnete erkrankungen | |
WO2014060486A1 (en) | Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample | |
Nimer | Mass Spectrometry as Discovery Platform for Candidate Metabolite of Non-Alcoholic Steatohepatitis (NASH) | |
Lundin | Biomarker discovery in diabetic nephropathy by targeted metabolomics | |
WATKINS et al. | Sommaire du brevet 2678670 | |
WATKINS et al. | Patent 2678670 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AC | Divisional application: reference to earlier application |
Ref document number: 2057473 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: METABOLON, INC. |
|
17P | Request for examination filed |
Effective date: 20131231 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20140130 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170223 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2057473 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 934522 Country of ref document: AT Kind code of ref document: T Effective date: 20171015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007052621 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20171004 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 934522 Country of ref document: AT Kind code of ref document: T Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180204 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180104 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180105 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007052621 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
26N | No opposition filed |
Effective date: 20180705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070808 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171004 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230527 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230828 Year of fee payment: 17 Ref country code: CH Payment date: 20230903 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230825 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240828 Year of fee payment: 18 Ref country code: IE Payment date: 20240827 Year of fee payment: 18 |